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ABSTRACT OF THE DISSERTATION
The Role of DNMT3A in Acute Myeloid Leukemia Pathogenesis
by
Christopher Browning Cole
Doctor of Philosophy in Biology and Biomedical Sciences
(Immunology)

Washington University in St. Louis, 2016
Professor Timothy Ley, Chairperson

Loss of function mutations in the DNA methyltransferase DNMT3A are highly recurrent in acute
myeloid leukemia (AML). DNMT3A and the highly homologous gene DNMT3B encode the two
methyltransferases that are primarily responsible for mediating de novo methylation of specific
DNA sequences during cellular differentiation. DNMT3A mutations are mutually exclusive of
several translocations that create oncogenic fusion genes (PML-RARA, RUNX1-RUNX1T1,
CBFB-MYH11, and MLL-X), suggesting that these fusions may require functional DNMT3A to
initiate leukemogenesis. Using bone marrow cells from a constitutive Dnmt3a null mouse, we
show that loss of Dnmt3a caused a striking loss of DNA methylation throughout the genome of
bone marrow cells, and a complete loss of methylation at hundreds of specific loci, suggesting
that these regions are entirely dependent on Dnmt3a for maintaining normal methylation
patterns. Using both retroviral vectors and a transgenic model, we demonstrated that the
methyltransferase activity of Dnmt3a but not Dnmt3b is required for aberrant self-renewal ex
vivo that is driven by PML-RARA (but not RUNX1-RUNX1T1 or MLL-AF9); further, the PMLRARA competitive transplant advantage and leukemia generation both required Dnmt3a. In
contrast, Dnmt3a was not required for leukemia generation caused by MLL-AF9, which is known
to have a requirement for Dnmt1 activity. Together, these findings demonstrate that PML-RARA
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is specifically dependent on Dnmt3a to drive leukemogenesis, and may explain why DNMT3A
mutations are mutually exclusive of PML-RARA in AML patients.
While the most common mutation in DNMT3A in AML patients is the missense mutation R882H,
other heterozygous mutations produce frameshifts, premature stop codons, or deletions of the
entire coding sequence of the gene, strongly suggesting that these mutations lead to simple
haploinsufficiency for DNMT3A. To test the hypothesis that Dnmt3a haploinsuffiency may
initiate AML, we performed a long-term tumor watch comparing wild-type mice (Dnmt3a+/+) to
mice carrying one wild-type Dnmt3a allele and one targeted allele that contains a neomycinresistance cassette inserted into the sequence coding for the catalytic domain of the protein,
producing a true null allele (Dnmt3a+/- mice). At 6 weeks of age, Dnmt3a+/- mice have normal
hematopoiesis, with no detected differences from wild-type littermates in myeloid, lymphoid,
erythroid, or stem/progenitor populations in the bone marrow or spleen. However, after 1.5
years of age, 15/43 Dnmt3a+/- mice (35%) became moribund and were euthanized for
pathologic evaluation, and at conclusion of the tumor watch at 2 years similar pathologic
findings were observed in an additional 9 Dnmt3a+/- mice, for an overall disease penetrance of
24/43 (56%). In contrast, 0/20 WT littermate control animals developed myeloid malignancies
over the same time period. Based on flow cytometric and morphologic findings, we classified 16
splenic tumors according to the Bethesda criteria: 11/16 had myeloid proliferative disease/MPD,
2/16 had myeloid leukemia with maturation, 2/16 had MPD-like myeloid leukemia, and 1 case
had myeloid sarcoma. Six tumors out of 18 tested were able to successfully engraft and lead to
lethal disease in sublethally irradiated wild-type recipients, providing further evidence that these
tumors represent transplantable, cell-autonomous myeloid malignancies. Exome sequencing of
engrafted tumors revealed mutations in the Ras/MAPK pathway, including the canonical gain-offunction mutation Kras G12C, a Ptpn11 E76K mutation, and a missense mutation in the tumor
suppressor Neurofibromatosis 1 (Nf1). Importantly, 9/51 AML samples with DNMT3A mutations
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in the TCGA AML cohort also contained activating NRAS or KRAS mutations. Examination of
the Dnmt3a locus in 4 sequenced samples revealed no evidence for mutations in or deletions of
the residual wild-type Dnmt3a allele. These data strongly suggest that Ras/MAPK pathway
mutations can cooperate with Dnmt3a haploinsufficiency to induce AML in C57Bl/6 mice and in
humans.
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Chapter 1

Introduction
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Section 1: Whole Genome Sequencing and the Genetics of AML
1.1 Historical Background on the Genetics of AML
Acute myeloid leukemia (AML) is a group of heterogeneous hematologic malignancies
which are all characterized by the accumulation of immature myeloid “blast” cells in the bone
marrow and blood. Aberrantly proliferating blast cells preclude the development of normal
hematopoietic cells and lead to cytopenias, immune compromise, and death. No targeted
therapy is available for most subtypes of AML, and the 5-year survival for these patients with
conventional chemotherapeutic treatment remains at a dismal 45%1.
Historically, efforts to understand the pathogenesis of acute myeloid leukemia relied on
grouping similar cases according to morphology of the leukemic cells, eventually being
systematized in the FAB (French-American-British) System2. One such example was acute
promyelocytic leukemia (APL), which was noted as early as the 1950s to comprise a distinct
diagnostic entity marked by blasts resembling normal promyelocytes and an explosive
presentation with disseminated intravascular coagulation and rapid lethality3. Subsequently, an
increased appreciation of the causal role of genetic mutations in oncogenesis led to a focus on
the genetics of acute myeloid leukemia and other cancers in the hopes of identifying driver
mutations that might be used to stratify risk or ideally result in mutation-specific targeted
therapies. In the case of acute promyelocytic leukemia, identification of the causative mutation
was greatly facilitated by the observation of a characteristic t(15;17) chromosomal translocation
in >90% of APL patients by Janet Rowley and colleagues4. The resulting translocation gene
product, PML-RARA, was cloned and has since been decisively established by our group and
others as the key initiating event in the promyelocytic subtype of AML5–9. Similar efforts have
identified an initiating role for other common AML translocation products, including RUNX1RUNX1T110, MYH11-CBFB11, and a variety of MLL-fusion genes12–14.
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By comparison with leukemias with recurrent chromosomal translocations, AML cases
that lack recurrent chromosomal abnormalities (normal karyotype or NK-AML) did not provide a
good starting point for finding causative genetic lesions. Recurrent internal tandem duplication
mutations in the tyrosine kinase FLT3 were found serendipitously by Nakao and colleagues
when expression studies on AML patients detected an RT-PCR product of aberrantly increased
length in several patients15. Targeted sequencing efforts subsequently uncovered these FLT3
ITD mutations and other mutations in FLT3 in approximately 25% of AML patients16–18.
Discovery of another recurrent mutation in NK-AML, a frameshift insertion leading to aberrant
cytoplasmic localization of the NPM1 gene product (NPMc mutations), was aided by the fact
that the gene had already been implicated as a recurrent fusion partner with various genes in
AML cases with recurrent cytogenetic abnormalities19–21. A subset of NK-AML patients were
also found to display aberrant cytoplasmic localization of the NPM1 protein and targeted
sequencing efforts of the NPM1 gene then uncovered recurrent frame-shift mutations in these
patients22. Although, these genes were discovered almost serendipitously, approaches to find
the other recurrently mutated genes in AML patients needed to be unbiased, and to explore all
regions of the genome.

1.2 Application of Next-Generation Sequencing in AML
The advent of whole-genome sequencing has greatly accelerated the search for driver
mutations in leukemia, and has led to the discovery of recurrent mutations in several genes
which had not previously been implicated in cancer, such as the DNA methyltransferase
DNMT3A23, the metabolic enzymes Isocitrate Dehydrogenase (IDH) 124 and 225, multiple
components of the spliceosome complex (including U2AF1)26, and all members of the cohesin
complex27. The ability of whole-genome sequencing to survey the entire genome in an
unbiased manner has been crucial for the discovery of these novel mutations in unsuspected
genes, and has implicated entirely new cellular pathways in leukemogenesis.
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In addition to allowing the discovery of these new mutations, whole-genome sequencing
has provided the ability to focus on the mutational profile of individual patients and determine
which genes are affected in a given patient’s cancer. This new technology has facilitated two
entirely new types of studies that promise to have far-reaching implications for our
understanding of leukemia biology, as well as our ability to develop improved therapeutics. The
first type of study is the ability of deep sequencing to interrogate the clonality of leukemia.
Studies from our lab and others have demonstrated that a given patient’s leukemia nearly
always consists of multiple clones, including a founding clone and one or more subclones that
are derived from it28–30. The clonal architecture of a leukemia can be inferred using deep
sequencing, in which mutations with similar variant allele frequencies (VAF) form clusters that
represent the founding clones or subclones. One study from our group utilized exome
sequencing on the progeny of individual hematopoietic stem/progenitor stem cells from normal
volunteers to survey to determine how many mutations are “background” mutations present in
normal hematopoietic cells prior to transformation28. This study discovered that the majority of
mutations present in leukemias are likely already present in the hematopoietic stem cell in which
the initiating mutation occurred. In addition, the clone with the initiating mutation acquires a
small number of cooperating mutations to form the founding clone (in some cases as few as 1
or 2 mutations), and then additional mutations are acquired in the subclones. A subsequent
study demonstrated that when transplanted into immunologically impaired mice, individual
subclones may be selected for during the engraftment process, and that resultant xenografted
leukemias are generally enriched for a single subclone, and thus may not adequately reflect the
clonal diversity of the primary tumor30.

1.3 Mutational Patterns and Clonality in Tumors
Whole genome sequencing has revolutionized studies of the mutational patterns within
individual leukemias. It had long been theorized that mutations that tend to occur together have
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a cooperative effect, where the second mutation is able to augment the oncogenic effect of the
first, providing an additional advantage to the developing cancer which is either additive to or
synergistic with the initiating mutation. Elegant targeted sequencing studies by Vogelstein and
colleagues provided clinical evidence for this hypothesis, by elucidating one temporal sequence
of acquired mutations in colon cancer; the sequential addition of mutations drives disease
progression from benign adenoma to full-blown colonic adenocarcinoma in a subset of
patients31. Direct in vivo experimental evidence for cooperativity has come from transgenic
mouse models. For example, sequencing of tumors from PML-RARA mice uncovered the
spontaneous acquisition of Jak1 V657F mutations, suggesting that gain-of-function mutations in
this tyrosine kinase cooperate with PML-RARA to drive leukemogenesis32. This hypothesis was
experimentally verified by transducing bone marrow from young PML-RARA+/- mice with
retrovirus encoding the corresponding mutated human gene JAK1 V678F, which led to greatly
accelerated onset of disease in recipients when compared with PML-RARA+/- bone marrow
transduced with an empty vector control.
The opposite of cooperativity is mutual exclusivity, i.e. mutations that never occur
together in an AML sample. A striking example from whole genome sequencing of AML
patients is that DNMT3A mutations almost never occur in AML patients with the common AMLinitiating fusion genes MLL-X, RUNX1-RUNX1T1, MYH11-CBFB, and PML-RARA27,28. This
mutual exclusivity suggests several possible interaction scenarios: 1) the two mutations act in
the same pathway and are functionally redundant, so there is no selective pressure for a cancer
cell to acquire both mutations, 2) the two mutations have antagonistic or synthetically lethal
effects, 3) functional DNMT3A enzyme is required for these fusion proteins to drive
leukemogenesis. In this thesis, a variety of experiments were performed to assess which of
these biological scenarios accounts for the mutual exclusivity of the common AML fusions and
DNMT3A mutations.
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Section 2: DNMT3A Mutations in AML
2.1 DNMT3A Mutations are highly recurrent in AML and Carry a Poor Prognosis
Recent whole genome sequencing efforts by our group have discovered mutations in the
DNA Methyltransferase 3A (DNMT3A) gene in approximately 37% of AML patients with a
normal karyotype (22% of all cases)23. These mutations are almost always heterozygous, and
have been demonstrated by our group and others to be associated with high blast count,
advanced age, and poor prognosis23,33–35. In addition, these mutations have been demonstrated
to be stable at relapse35, indicating that they are probably in the founding clone for most
patients. DNMT3A mutations are enriched for changes at a single amino acid in the catalytic
domain, R882 (37 out of 62 DNMT3A-mutated patients in our study), but other patients had
nonsense, splice-site, and frame-shift mutations, and in one case, deletion of a 1.5 MB region
including DNMT3A (Figure 1)23. Studies from our group and others confirmed that these
heterozygous R882 mutations lead to a hypomorphic effect on the methyltransferase activity of
the enzyme, and also a dominant negative affect on the WT DNMT3A present in the same AML
cells36–38. DMNT3A with the R882H mutation forms stable heterodimers with WT DNMT3A,
disrupting the ability of the wild-type DNMT3A protein to form active tetramers. The high
prevalence, poor prognostic association, and stability throughout the course of disease strongly
argue for a key pathogenetic role for DNMT3A mutations in AML.

2.2 DNMT3A Haploinsufficiency as a Possible Disease Mechanism
There are two distinct groups of DNMT3A-mutated AML patients. The first and most
common comprises those with point mutations at amino acid R882. These patients are
predicted to have very low DNMT3A activity due to the hypomorphic activity of the R882 mutant
protein and the dominant negative effect of the mutated allele23. Correspondingly, these cases
have been demonstrated to have canonical CpGs that are hypomethylated when compared to
the same sequences in AML patients without DNMT3A mutations36. The other groups consists
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of non-R882 mutations. While some are missense mutations in functional domains, others are
predicted to have translational effects that would disrupt the coding sequence of one allele by
introducing premature stop codons, frameshifts, or whole gene deletions23. Many of these
mutants would not be predicted a priori to have dominant negative activity, suggesting that they
create haploinsufficiency for DNMT3A. This raises the intriguing possibility that simple
haploinsufficiency for DNMT3A may also be an initiating event for AML in these patients.
Dnmt3a conditional null mice exhibit an aberrant expansion and loss of differentiation
potential in the long-term hematopoietic stem cell compartment when serially transplanted
39

(described below). However, conditional Dnmt3a+/- mice have not been similarly

characterized. Constitutive Dnmt3a-/- mice carrying knockout alleles of Dnmt3a (which produce
no detectable Dnmt3a protein) die with progressive runting at age 3 to 4 weeks, whereas mice
with one Dnmt3a KO allele do not display runting or early lethality34. No gross abnormalities
have been reported in Dnmt3a+/- mice, except for an increased variation in body size which
may reflect instability in quantitative traits induced by DNA hypomethylation40. Notably,
hematopoiesis in Dnmt3a+/- mice has not been fully characterized, and these mice have never
been monitored in a long-term tumor watch. Thus the effects of loss of one copy of DNMT3A on
normal hematopoiesis and leukemogenesis remain to be experimentally tested.

Section 3: DNMT3A and DNMT3B mediate DNA methylation involved in cell differentiation and
loss of pluripotency
3.1 Structure and Function of DNMT3A and DNMT3B
DNMT3A and the highly homologous enzyme DNMT3B are the two known de novo DNA
methyltransferases, which are characterized by the ability to introduce DNA methylation to
sequences which are not methylated on either strand41. In contrast, DNMT1 is the maintenance
DNA methyltransferase, and is responsible for methylating the unmethylated strand of a
hemimethylated sequence after DNA replication, thus maintaining methylation patterns after cell
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divisions. DNMT3A and DNMT3B share similar domain structures, including a catalytic
methyltransferase domain, an ADD domain mediating protein-protein interactions as well as
interaction with the unmethylated histone tail of H3K4, and a PWWP domain necessary for
targeting to heterochromatin via recognition of H3K3642. Both proteins have been primarily
studied for their ability to introduce DNA methylation to the C5 carbon of cytosine in CpGdinucleotides (so-called CpG residues), since this is the most prominent DNA methylation
observed in the genome, but the enzymes also possess the ability to methylate cytosine in CA
and to a lesser extent CT and CC dinucleotide motifs43. The importance of this non-CpG
methylation remains unclear.

In addition, DNMT3A and DNMT3B have been shown to

physically interact with each other, and with DNMT1, in vitro44.
Despite these similarities, DNMT3A and DNMT3B exhibit differences in flanking
sequence specificity both in an in vitro cell-free assay and in an “in vivo” yeast episome
system45. These distinct preferences likely result from differences in the amino acids in the
catalytic domain, which have been demonstrated by X-ray crystallography to make contact with
the nucleotides flanking the CpG residue42,46. Recently ChIP-seq studies have compared genes
bound by DNMT3A vs DNMT3B in NCCIT cells (a mixed germ cell tumor cell line), either
undifferentiated or induced to differentiate with retinoic acid. In the undifferentiated cells, there
was substantial overlap between the genes bound by DNMT3A and DNMT3B; after retinoicacid-induced differentiation, less than 50% of bound genes were shared between the two
enzymes47. This study was not capable of elucidating cause and effect relationships between
binding of the DNMTs and DNA methylation, and an important caveat of ChIP-seq studies like
this one is that binding of a DNA methyltransferase does not necessarily correspond to the
induction of methylation. Nevertheless, this study indicates that in addition to differences in
flanking site preference for the two de novo DNA methyltransferase enzymes in vitro and in the
episomal system, there are also differences in the DNA sequences that are bound. This
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suggests that different genes may have different potentials to be regulated by DNA methylation
mediated by DNMT3A vs DNMT3B in vivo.

3.2 Importance of DNMT3A and DNMT3B for de novo DNA Methylation in Development
As the mediators of de novo DNA methylation, DNMT3A and DNMT3B have been
demonstrated to play a key role in catalyzing the methylation of genomic DNA required for an
organism to normally develop and differentiate34,42,48. The phrase “de novo DNA methylation”
originally referred to the experimental observation that exogenously induced viral sequences
were capable of being methylated and having their expression silenced in mammalian cells49;
this activity was subsequently discovered to be dependent on DNMT3A/B34. Later it was
observed that after a sweeping phase of demethylation in the fertilized gamete, embryonic cells
subsequently exhibited active methylation at specific sequences50. This developmental
methylation process was termed “de novo” methylation to differentiate it from the process by
which newly synthesized strands of DNA have their methylation copied to the daughter strand
(primarily by DNMT1) to maintain methylation patterns after cell divisions (so-called
maintenance methylation)51.
De novo DNA methylation is thought to be crucial for an organism’s somatic cells to turn
off pluripotent stem cell gene expression programs and undergo tissue specific differentiation.
Indeed, mouse ES cells that are null for Dnmt3a and 3b lose the ability to differentiate with
repeated passages51. Both Dnmt3a and Dnmt3b knockout mice suffer from early lethality, with
Dnmt3b mice dying in utero due to cardiac defects and hemorrhage, and Dnmt3a knockout mice
dying at 3-4 weeks of age with severe runting34. In humans, biallelic germline mutations in
DNMT3B lead to the ICF syndrome (Immunodeficiency—Centromeric instability—Facial
anomalies), an autosomal recessive syndrome characterized by multiple developmental defects,
hypomethylation of satellite repeats, and developmental defects in lymphocytes52. The
lymphocyte development defects result from hypomethylation of pericentromeric chromatin,
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which facilitates the formation of unbalanced translocations and ultimately, the induction of
apoptosis resulting in lymphopenias. Several of these mutations have been demonstrated to
result in loss of Dnmt3b function; knock-in mouse models of two common ICF mutations, A609T
and D823G, recapitulated features of the human disease, including low body weight and
craniofacial abnormalities, apoptotic death of T cells, and hypomethylation of repetitive genomic
sequences.53 De novo germline mutations in DNMT3A were recently reported in a cohort of
British teenagers, and were associated with a syndrome of developmental intellectual disability,
large body size, and distinctive facial features54. The translational consequences of these
mutations, which are primarily point mutations in all three of the functional domains of the
enzyme (ADD, PWWP, and methyltransferase domains) remain to be determined, and the
mutational pattern is notably different from that observed in AML patients23,54. It is therefore
unclear at present unclear whether this syndrome represents DNMT3A haploinsufficiency or
dominant negative effects of the mutant protein on the residual wild-type allele. It is tempting to
speculate that the large body size in these teenagers is mechanistically related to the variability
in body size observed in Dnmt3a+/- mice discussed above40. Because these patients are very
young and the mutations are de novo rather than inherited, it also remains to be seen whether
these individuals have an increased risk of hematologic malignancy.

3.3 DNMT3B Has a Tumor Suppressive Role in Mouse Lymphoma Models
In contrast to the high frequency ofDNMT3A mutations in AML, DNMT3B mutations are
rare (2/200 in the TCGA study)27. One case had a R538C mutation, and the second had an outof-frame fusion of DNMT3B which presumably inactivated that allele. An expression of a
dominant negative isoform of DNMT3B lacking the catalytic domain, DNMT3B7, has been
observed in some lymphoma patients, and is postulated to facilitate oncogenesis by inhibiting
the activity of the wild-type DNMT3B allele55. In order to test this hypothesis, a transgenic
mouse was constructed in which lymphomas spontaneously develop due to the overexpression
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of Myc in B cells (Eu-Myc mice56 The role of Dnmt3b expression was investigated by crossing
these mice to a transgenic mouse expressing DNMT3B755,and then to a mouse with one
knockout allele of Dnmt3b (Dnmt3b+/-)57. Constitutive DNMT3B7 overexpression was found to
lead to developmental defects reminiscent of the phenotype of Dnmt3b-/- mice, whereas
conditional expression of the Eu-Myc driver led to an increased incidence of mediastinal
lymphomagenesis. The Dnmt3b+/- mice likewise exhibited an increased incidence of
mediastinal lymphomas, and targeted sequencing indicated that the remaining wild-type allele
had not been mutated. Interestingly, mediastinal tumors from the DNMT3B7 expressing mice
were found to have increased 5-meC levels relative to mediastinal tumors from Eu-Myc mice
with a wild-type Dnmt3b allele, and tumors from Dnmt3b+/- mice were found to have the highest
level of methylation of the three genotypes. Similar results were obtained in another Eu-Myc
lymphoma model, in which Dnmt3b was selectively knocked out in T cells under the control of
the EμSR-tTA; the resultant Dnmt3b-/- mice developed an increased incidence of T cell
lymphoma58. In this model, DNA methylation levels by HPLC exhibited the expected pattern, in
which Dnmt3b loss led to hypomethylation compared to tumors from Dnmt3b+/+ controls.
Collectively, these results demonstrate that loss of one or both copies of Dnmt3b is capable of
facilitating lymphomagenesis in the context of Eu-Myc mouse models.
These studies of mouse lymphoma models do not address the question of whether
Dnmt3b loss would contribute to the development of myeloid malignancies; the role of Dnmt3b
in mouse models of AML pathogenesis remains to be tested. Intriguingly, although DNMT3B is
highly expressed in AML samples, most patients predominantly express isoforms such as
DNMT3B3 which, like DNMT3B7 , lacks the exons coding for the catalytic domain of the protein
(Russler-Germain et al 2014)36. This suggests that these isoforms are catalytically inactive, and
it is formally possible that they may interact with the DNMT3B and/or DNMT3A proteins in a
dominant negative manner.
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3.4 Loss of Dnmt3a Leads to Impaired Hematopoietic Differentiation and Increased Self-renewal
Dnmt3a and Dnmt3b are highly expressed in murine HSCs, and their expression
decreases in more differentiated cells59. Surprisingly, a conditional hematopoietic knockout
mouse with a large deletion in the catalytic domain of Dnmt3a exhibits grossly normal resting
hematopoiesis39. However, subtle abnormalities in the stem cell population of these mice were
discovered when the bone marrow from a Dnmt3a -/- mouse was mixed with wild type bone
marrow and transplanted into irradiated recipients29. Serial competitive transplants resulted in
progressive increases in the size of the long-term stem cell compartment, combined with
progressive decreases in the ability of the Dnmt3a-/- stem cells to develop into mature,
differentiated cells. Although these mice did not develop AML (at least in this competitive
transplant experiment) their stem cells exhibit impaired differentiation and increased selfrenewal, which are two hallmarks of leukemic blasts.

Section 4: Role of DNA Methylation in Modulation of Gene Expression and Cancer
4.1 Relationships between DNA Methylation and Gene Expression
The canonical relationship between DNA methylation and repression of gene expression
was based on studies of the promoters of genes that contain a CpG island (a CpG-dense region
usually defined as >=1KB with at least a 50% increase in CpG density over the observed ratio in
the rest of the genome)60. These promoters, known as CpG-island promoters, tend to have a
high degree of promoter methylation when repressed, and conversely are mostly unmethylated
when the gene is highly expressed. It was subsequently discovered that only a minority of CpG
islands, including those in promoters, are methylated in normal cells, and that CpG-island
promoters with a high degree of methylation tend to be those which are stably silenced for long
periods of time, such as imprinted genes, inactive X chromosome genes, and genes that are
specifically expressed in germ cells61. Additionally, genes with CpG-island promoters were
found to be predominantly housekeeping genes and tumor suppressors. Other genes with more
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dynamic, tissue-specific expression usually lack CpG islands, but many have CpG residues
near their transcription start site that are capable of being methylated.
The mechanisms by which many heavily methylated CpG-island promoters lead to gene
silencing (usually via repressive chromatin remodeling) have been well elucidated60,62.
Generally, methylated DNA binding proteins stabilize nucleosomes with the repressive H3K9
mark, which in turn recruits histone deacetylases leading to the formation of heterochromatin.
In contrast, the mechanisms that lead to DNA methylation in promoters that lack CpG islands
appear to be varied and complex. In some cases, such as OCT4 target sites in embryonic stem
cells, DNA methylation appears to directly inhibit binding of a transcription factor. In other
cases, proteins with methylated DNA binding domains may directly repress transcription by
competing with transcription factors for binding sites, or by recruiting co-repressors that lead to
the formation of heterochromatin60,63,64.
Aside from promoters, various other functional units in the genome are capable of being
methylated, including gene bodies, insulators, and enhancers. Gene body methylation tends to
be positively correlated with gene expression65, and may also regulate alternative splicing66. In
addition, some gene bodies possess CpG islands. The function of these CpG island gene
bodies is poorly understood, but one possibility is that they serve to regulate the transcription of
as yet undiscovered transcripts within genes65. Methylation at insulators has been
demonstrated to decrease the ability of insulators to repress their target genes (for example,
near imprinted loci)67, but it is unclear whether this principle holds outside of the special case of
imprinting. Similarly, enhancer methylation has been demonstrated to lead to gene silencing in
reporter assays68.
Other groups have expanded their methylation analyses from individual CpG islands to
larger, surrounding genomic regions. Studies from Andrew Feinberg’s group and others have
demonstrated a high inverse correlation between the methylation state of the regions directly
flanking CpG islands, (called CpG shores) and their neighboring genes69. CpG shores from
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different normal tissues also displayed a greater degree of differential methylation than CpG
islands themselves, and were also more differentially methylated when compared to tumors
derived from that same tissue (e.g. colonic adenocarcinoma vs normal colonic tissue). Peggy
Goodell’s group has used whole genome bisulfite sequencing of hematopoietic stem cells to
demonstrate the existence of large hypomethylated regions they termed “canyons”, which are
enriched for genes involved in transcriptional regulation, including the HOX genes70.
Interestingly, the highly methylated boundaries of these canyons were “eroded” and either
expanded or contracted in size in Dnmt3a-null hematopoietic stem cells, leading the authors to
posit that maintaining these boundaries and thus stabilizing the expression of genes associated
with hypomethylated “canyons” is a specific function of Dnmt3a.

4.2 Altered DNA Methylation is a Hallmark of Cancer Cells
A pathogenetic role for de novo DNA methylation in cancer is supported by the fact that
many tumors show marked global DNA methylation abnormalities, which are thought to facilitate
their aberrant self-renewal capability and lack of normal differentiation71. Studies from different
malignancies have noted that tumors can be distinguished by methylation state from normal
tissues using unsupervised clustering algorithms69,72,73. In general, cancer genomes tend to be
globally hypomethylated when compared to the matched normal tissue, but focally
hypermethylated at tumor suppressor genes71. In stark contrast with normal cells, CpG-island
promoters are often hypermethylated in tumor samples. For example p15, a cyclin-dependent
kinase inhibitor and well-known tumor suppressor that is epigenetically silenced in
approximately 60% of AML cases due to hypermethylation in its promoter region, appears to be
actively silenced in a manner that is dependent on transcription of an antisense RNA74. In most
cases, it is unclear whether hypermethylation at tumor suppressors is directly induced by an
oncogene, or whether it occurs stochastically and is then selected for by transformation. Direct
recruitment of DNA methyltransferase to repress target genes has been suggested
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experimentally for various transcription factors important in leukemia including PU.175 and
MYC64, and oncogenic drivers such as RAS have been demonstrated to indirectly induce DNA
methylation at target genes through the cooperation of a third corepressor protein76. As
discussed below, there is evidence that PML-RARA is capable of directly interacting with
DNMT3A and thus inducing hypermethylation and gene expression changes, but the
importance of this direct induction of methylation for PML-RARA’s ability to alter gene
expression remains to be established.
The functional importance of DNA methylation in cancer is illustrated by the activity of
methylation inhibitors such as 5-Azacytidine in some cancer types, including AML77. In addition,
the forced expression of genes that are selectively hypermethylated in cancer cells has been
shown to result in cancer cell death78. The mediators of the aberrant DNA methylation in cancer
largely remain to be elucidated, but a role for DNMT3A and DNMT3B is strongly suggested by
the known de novo DNA methylation functions of these genes, and the fact that they are both
highly expressed in a variety of malignancies, including AML59. In the case of DNMT3A R882H
mutations, DNA methylation arrays have demonstrated the existence of canonical
hypomethylated CpGs that distinguish these patients from other NK-AMLs with wild-type
DNMT3A, strongly suggesting that these specific aberrantly hypomethylated CpGs result
directly or indirectly from the DNMT3A R882 mutation36.

4.3 Mutations in the DNA Methylation Pathway are Common in NK-AML
As mentioned above, DNMT3A mutations are prevalent in NK-AML, but are mutually
exclusive of the common initiating chromosomal translocations, including PML-RARA.
Importantly, mutations in several other genes that target the DNA methylation pathway have
recently been identified in AML cases. Specifically, the IDH1 and IDH2 mutations, which were
originally thought to confer a metabolic effect because of their known role in the citric acid cycle,
were subsequently demonstrated to produce a neomorphic substrate that inhibits the DNA
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methylation pathway and thus leads to hypermethylation in AML cases79. Likewise, TET2
mutations disrupt the removal of methyl-CpGs from DNA by subsequent oxidation steps,
resulting in a global increase in CpG methylation in AML patients with this mutation80. IDH
mutations and TET2 mutations appear to be mutually exclusive27, which is in line with their
predicted antagonistic effects on the DNA methylation pathway, whereas DNMT3A mutations
and IDH mutations tend to co-occur for reasons that are not yet clear.
Collectively, mutations affecting the DNA methylation pathway are rare in cases with the
common initiating chromosomal translocations. For example, the TCGA study of AML identified
0/16 PML-RARA cases, 1/7 RUNX1-RUNX1T1 cases, 0/11 MYH11-CBFB cases, and 1/11
MLL-X fusions with DNA methylation pathway mutations27. As discussed above, this raises the
intriguing possibility that these chromosomal fusions require a functional DNA methylation
pathway in order to drive leukemogenesis. Further support for this hypothesis comes from the
fact that each of the four common translocations can be distinguished from each other, and from
all other leukemias, by unsupervised clustering of the most differentially methylated CpGs in
AML samples27 (see Figure 2 and related discussion below). The fact that each of these
chromosomal fusions is associated with a specific set of methylation changes suggests the
importance of DNA methylation for their ability to drive disease, and may provide an explanation
for the absence of mutations in the DNA methylation pathway in these cases.

Section 5: PML-RARA and its Relationship to DNA Methylation
5.1 PML-RARA is an Oncogenic Fusion Protein which Represses Myeloid Maturation
Chromosomal translocations involving the transcription factor Retinoic Acid Receptor
Alpha (RARA) are pathognomonic for Acute Promyelocytic Leukemia. The most common of
these translocations, t(;15,17)(q22;q21), fuses RARA to the nuclear protein Promyelocytic
Leukemia (PML)81. Wild type RARA is a key regulator of normal myeloid differentiation82,83. By
binding to promoters containing Retinoic Acid Response Elements (RAREs) and repressing
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them, RARA inhibits myeloid maturation until exposure to its ligand, retinoic acid, causes its
release from DNA84. In contrast, the PML-RARA fusion protein displays aberrant
oligomerization and nuclear localization85,86, and binds repressively to DNA in a manner that is
unresponsive to physiologic concentrations of retinoic acid, but responds to pharmacologic
inhibition by the ligand All-Trans-Retinoic Acid (ATRA), which is now a first-line therapy for
APL84. ATRA binding causes release of PML-RARA protein from target promoters, degradation
of PML-RARA, subsequent re-expression of myeloid differentiation genes, and induction of
myeloid differentiation.

5.2 PML-RARA is Associated with DNA-Methylation and Silencing of Key Target Genes, and
Interacts with DNMT3A and DNMT3B
PML-RARA has been demonstrated to repress gene expression by interacting with
several corepressor molecules, including HDAC3, NRCP187, and MBD 1 88. In addition, a
physical interaction and colocalization of DNMT3A and PML-RARA has been demonstrated in
cell lines89. Investigations at known PML-RARA target genes, such as the tumor suppressor
RARB, have established that PML-RARA causes repression of gene expression and
hypermethylation of the RARB promoter in the NB4 cell line (which is derived from an APL
patient with t(15;17)) and in patient samples. ATRA treatment leads to reduced methylation of
DNA near the RARB promoter, and re-expression of the gene90,91. Both DNMT3A and DNMT3B
are highly expressed in NB4 cells, and were found by ChIP-qPCR to be bound (along with PMLRARA) at the RARB promoter91. Interestingly, ATRA treatment led to a rapid and potent
downregulation of both DNMT3A and DNMT3B expression in NB4 cells and in patient samples
(by western blotting). Downregulation was detectable as early as 4 hrs after ATRA addition to
NB4 cells, and preceded induction of differentiation, demonstrating that it was not a secondary
effect of gene expression changes related to differentiation. The importance of methylation for
maintaining repression of RARB was demonstrated by the fact that this repression can be
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partially relieved by pharmacologic inhibitors of DNA methylation, such as 5-azacytidine, and
these synergize with ATRA to cause the release of PML-RARA, reduced promoter methylation,
and myeloid differentiation in NB4 cells91. These experiments provide support for a model in
which PML-RARA recruits DNMT3A and/or DNMT3B to promoters, leading to de novo promoter
methylation, induction of repressive chromatin changes, and repression of target gene
expression.

5.3 The Relationship between PML-RARA binding and DNA methylation remains to be fully
elucidated
Recent genome-wide approaches in APL cell lines have confirmed the association
between PML-RARA binding at promoter regions, the presence of transcriptionally repressive
histone modifications, and repression of gene expression. A ChIP-Chip study of the PR-9 cell
line (containing zinc-inducible PML-RARA) used an anti-PML antibody with human promoter
and CpG arrays to discover 372 genomic regions that are bound when PML-RARA expression
is induced92. Subsequent ChIP experiments on the same cells revealed that virtually all PR
target binding sites exhibited increases in H3-K9 trimethylation, increased HDAC1 binding, and
decreases in H3 acetylation. These repressive chromatin changes were accompanied by
decreased gene expression for some of the target genes. A ChIP-Seq study of NB4 cells93
used antibodies against PML and against RARA, and then used a bioinformatics approach to
compute overlapping peaks between the two antibodies, which were presumed to correspond to
PML-RARA binding sites. This study found 2,722 unique PML-RARA binding sites in NB4 cells,
including sites in the gene body of DNMT3A and other epigenetic modifier genes such as
HDAC4, HDAC9 and PRMT3, as well as in genes encoding hematopoietic transcription factors,
such as RUNX1, GATA2, and PU.1. Early (24-48 hours) epigenetic and gene expression
changes in response to ATRA were examined using ChIP for histone acetylation and
methylation marks, and RNA polymerase II occupancy as a surrogate for gene expression.
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Only a small subset of PR target genes were found to be upregulated in response to ATRA at
this time point, and upregulated genes were found to be enriched for H3K9 trimethylation and
H3 acetylation.
In addition to confirming that PML-RARA binding is associated with repressive chromatin
conformations and decreased transcription of target genes, these studies demonstrated the low
predictive value of bioinformatically-driven, motif-based approaches to predict PR binding sites.
All studies found that only a small subset of bound loci possessed the canonical Retinoic Acid
Response Element that typifies wild type RARA targets92,93. This finding confirms in vitro
evidence that PML-RARA possesses novel sequence specificity compared to wild type PML
and RARA, and highlights the need for unbiased ChIP-sequencing approaches in order to
discover genuine PR targets.
Unsupervised clustering of APL samples based on methylation array data demonstrates
that APL samples have a methylation profile which distinguishes them from all other types of
AML (Figure 2, data from the TCGA study on AML, unpublished). Importantly, no study has
yet assessed the role of DNA methylation on the ability of PML-RARA to repress target genes.
In the above-mentioned ChIP-seq paper93, a GST-methyl DNA binding (methyl-cap) approach
coupled with ChIP-seq revealed what the authors describe as “a low level of methylation” near
PML-RARA peaks in NB4 cells, but the absence of a control makes their methylation data
impossible to interpret. Inferring relationships between the DNA methylation and expression
level of a given gene is complicated by the fact that genes have multiple CpG sites both in their
promoter and gene body regions, and it is not currently possible to computationally sum the
methylation states of all of a gene’s CpG sites to predict whether it will be “on” or “off.” Thus,
the most meaningful way to examine DNA methylation is by comparing the methylation state of
a given gene under two different conditions. In the case of PML-RARA, comparing the
methylation and gene expression status of cells that contain PML-RARA to those of normal
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hematopoietic cells that lack PML-RARA will better define the relationships between PML-RARA
binding, DNA methylation, and repression of gene expression.

Section 6: Application of Mouse Models to Genetic Studies of AML
6.1 Ctsg-PML-RARA mice develop APL and exhibit aberrant self-renewal ex vivo
To elucidate the role of PML-RARA in initiating leukemia, our lab developed a transgenic
mouse model in which control of the human PML-RARA gene is under control of the
endogenous mouse Cathepsin G regulatory locus, leading to expression of PML-RARA
primarily in myeloid progenitor cells (the Ctsg-PML-RARA mouse). This mouse spontaneously
develops APL with high penetrance (c. 60% in C57Bl/6 mice) and long latency (8-12 months for
most APLs), which is preceded by a mild proliferation of myeloid cells with normal maturation in
the bone marrow and spleen6. The disease phenotype of this mouse faithfully recapitulates
salient aspects of human APL, including the acquisition of genetic cooperating events, such as
an interstitial deletion of chromosome 2 (with loss of the PU.1 gene)94, and the ability to
cooperate with other mutations observed in APL patients, such as FLT3-ITD95 . The long
latency of the disease suggests the need for additional mutations to cooperate with PML-RARA,
as mentioned above. The cooperative ability of the Jak1 V657F mutation has been
experimentally verified. Intriguingly, when mice with the human CTSG-PML-RARA transgene
(also made in our lab) were crossed with a transgenic mouse overexpressing DNMT3A, the
resulting progeny exhibited decreased disease latency96, suggesting cooperativity between
DNMT3A and PML-RARA. However, the mechanistic nature of this cooperativity and the
relationship with DNA methylation was not evaluated.
Young, non-leukemic Ctsg-PML-RARA mice exhibit an abnormal “serial replating
phenotype”. This phenotype is measured with an assay where whole bone marrow cells are
plated in a semi-solid methocellulose medium; rare progenitor cells in the marrow give rise to
myeloid colonies that are subsequently replated. In the case of bone marrow from wild-type
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mice, the progenitors are not capable of forming colonies after the 2nd or third weekly replating.
However, cells from Ctsg-PML-RARA mice are capable of being serially replated, and form
myeloid colonies week after week. This phenotype has also been detected in other PML-RARA
mouse models6,9798, and is thought to be the earliest indicator of aberrant myeloid progenitor
self-renewal in these mice. The intimate link between this aberrant self-renewal and the
eventual development of leukemia was illustrated by the fact that a Ctsg-PML-RARA mouse
with mutations preventing sumoylation in PML-RARA lost its replating potential, and in turn, no
longer spontaneously developed APL98.

6.2 Retroviral Models of AML-Initiating Fusion Genes will Allow the Role of DNA Methylation in
Aberrant Self-renewal to be Experimentally Defined
In addition to genetically engineered mouse models, the biology of the common AMLinitiating translocations has been studied by retroviral overexpression studies, where the fusion
gene of interest is introduced into bone marrow cells from a wild-type mouse, and then the
transduced cells are studied either in vitro or transplanted into irradiated wild-type mice for in
vivo studies. In vitro studies have demonstrated that overexpression of PML-RARA97, MLLAF999, or AML-ETO100 is sufficient to induce a replating phenotype similar to that described
above for the Ctsg-PML-RARA mouse. One appealing feature of these retroviral models is that
they quickly induce an aberrant self-renewal phenotype in wild-type cells, which is one hallmark
of leukemia initiation. Additionally, the ability of these retroviruses to induce aberrant selfrenewal can be tested in the context of bone marrow with deficits in DNA methylation (e.g.
Dnmt3a-deficient marrow) in order to determine whether a functional DNA methylation pathway
is required for these fusion genes to drive aberrant self-renewal.

Section 7: Summary
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In this thesis, we will study mouse models of leukemia to provide a mechanistic
explanation for two clinical observations:
1) In addition to recurrent point mutations at amino acid R882, DNMT3A mutations include
premature stop codons, frameshift mutations, and whole gene deletions that are predicted to
lead to haploinsufficiency for the Dnmt3a protein. This suggests that Dnmt3a haploinsufficiency
may be able to initiate AML.
2) DNMT3A mutations are mutually exclusive of the common AML fusion genes, PML-RARA,
MLL-X, AML-ETO, and CBF-MYH11. There are multiple scenarios that could explain the
mutual exclusivity, including functional redundancy, antagonistic effects, and a requirement of
these fusions for functional DNMT3A to induce leukemogenesis.
In Chapter 2, we will test the common AML fusions for their ability to induce aberrant selfrenewal in a Dnmt3a-null mouse. We will further characterize the finding that PML-RARA
cannot induce replating in Dnmt3a deficient marrow by performing additional studies in a CtsgPML-RARA mouse lacking both copies of Dnmt3a.
In Chapter 3, we will test the ability of Dnmt3a haploinsufficiency to initiate AML in a mouse
model, and will further examine the effect of Dnmt3a loss on normal hematopoiesis and the
ability to induce competitive transplant advantage against wild-type in bone marrow
transplantation experiments.
In Chapter 4, we will summarize our results and consider future experiments in order to further
investigate the role of DNMT3A haploinsufficiency in AML and the role of functional Dnmt3a in
leukemias initiated by the common chromosomal fusions.
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Section 9: Figure Legends
Figure 1.
DNMT3A Mutations are Recurrent in AML. 188 bone marrow samples from AML patients were
banked at Washington University and all 24 exons of DNMT3A were amplified by PCR and
Sanger sequenced. Frequency of mutations including those at R882 is indicated by colored
dots, and the location of mutations is indicated relative to the methyltransferase (MTase), zinc
finger (ZNF), and proline-tryptophan-tryptophan-proline domains.

Figure 2.
Unsupervised Clustering Analysis Demonstrates an APL Methylation Signature. DNA from 178
AML patients was hybridized to Illumina Human Methylation 450 microarrays and unsupervised
clustering was performed using a K-means algorithm. Mutation status for common recurrent
AML mutations is indicated for each patient. APL patients with PML-RARA form a contiguous
cluster indicating a common methylation signature (red arrow).
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Chapter 2

The PML-RARA fusion gene requires Dnmt3a to initiate APL
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2.1 Abstract
DNMT3A and DNMT3B encode the two DNA methyltransferases that are primarily
responsible for the de novo methylation of specific cytosine residues in CpG
dinucleotides during mammalian cellular differentiation. Loss-of-function mutations in
DNMT3A are highly recurrent in acute myeloid leukemia (AML), but are almost never
found in AML patients with translocations that create oncogenic fusion genes (e.g. PMLRARA, RUNX1-RUNX1T1, and MLL-AF9). To explore how DNMT3A is involved in the
function of these fusion genes, we used retroviral vectors to express PML-RARA,
RUNX1-RUNX1T1, or MLL-AF9 in bone marrow cells of wild-type (WT) or Dnmt3a
deficient mice; we also examined the phenotypes of hematopoietic cells from CtsgPML-RARA mice (which express PML-RARA in early hematopoietic progenitors and
myeloid precursors) with or without Dnmt3a. We demonstrate that the methyltransferase
activity of Dnmt3a—but not Dnmt3b—is required for aberrant self-renewal ex vivo that is
driven by PML-RARA, and that Dnmt3a is dispensable for self-renewal driven by
RUNX1-RUNX1T1 and MLL-AF9. Furthermore, both the PML-RARA-driven competitive
transplantation advantage and acute promyelocytic leukemia (APL) development
require Dnmt3a. Together, these findings suggest that PML-RARA has a unique
requirement for Dnmt3a to initiate APL in mice.
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2.2 Introduction
Recent efforts by our group and others have identified most of the highly recurrent
somatic mutations that are relevant for the pathogenesis of acute myeloid leukemia (1).
In addition to discovering recurrent mutations in genes that were not previously known
to be important for AML, patterns of mutational co-occurrence and mutual exclusivity
are providing important clues regarding the biology of pathways that may contribute to
this disease. Mutations in DNMT3A, one of the two mammalian de novo DNA
methyltransferases, occur in ~20% of patients with AML; however, they almost never
co-occur with the common chromosomal translocations that create fusion genes such
as PML-RARA, RUNX1-RUNX1T1 (also referred to as AML-ETO), and MLL-fusions
such as MLL-AF9 (1,2), suggesting a possible relationship between these fusion
oncogenes and a fully functional DNMT3A to initiate leukemia.
DNMT3A and the highly homologous enzyme DNMT3B are responsible for inducing
specific patterns of de novo DNA methylation in bone marrow stem/progenitor cells,
which is important for the ability of hematopoietic stem cells to develop into
differentiated peripheral blood cells (3-5). The most common DNMT3A mutation, which
leads to a heterozygous R882H amino acid change in the catalytic domain of the
enzyme, reduces DNMT3A methylase activity by 80% and, in a dominant negative
fashion, inhibits the ability of wild-type (WT) DNMT3A protein to form active
homotetramers (6,7). Although a requirement for functional DNMT3A has not been
tested for any of the common chromosomal translocations, all of these translocations
are associated with distinct DNA methylation signatures in primary AML samples,
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suggesting that alterations in DNA methylation are a common consequence of these
chromosomal alterations. In addition, previous studies have suggested a functional
relationship between PML-RARA and DNMT3A. PML-RARA is known to act as an
oncogenic transcription factor that is capable of initiating leukemia in mouse models (814), and has been shown to repress target genes by interacting with a co-repressor
complex that includes the methylated DNA binding protein MBD1 and DNMT3A (15-22).
At the RARB locus, the physical binding of PML-RARA coincides with recruitment of
DNMT3A, methylation of the RARB promoter, and silencing of gene expression (23).
However, it is not yet known whether PML-RARA requires DNMT3A to act as an
oncogene. Recent ChIP-seq studies in AML cell lines have shown that the DNA
methylation changes in close proximity to PML-RARA binding sites are relatively subtle
(24-25), suggesting that the functional relationship between PML-RARA and DNMT3A
on a whole genome level may be more complex than that observed at the RARB locus.

To directly test the hypothesis that AML-initiating fusion genes and DNMT3A mutations
are mutually exclusive because the fusions may require DNMT3A to exert their
activities, we utilized bone marrow cells from a previously described, constitutive
Dnmt3a null mouse; we tested the ability of three different fusion oncogenes to induce
aberrant self-renewal and leukemia in the absence of Dnmt3a. Our results show that
Dnmt3a (but not Dnmt3b) is required only for PML-RARA to induce aberrant selfrenewal in myeloid progenitor cells, and to initiate APL in vivo. It is not required for the
leukemogenic potential of MLL-AF9, or the self-renewal of myeloid progenitors induced
by RUNX1-RUNX1T1. These data point out the complexity in understanding the mutual
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exclusivity of AML mutations, but demonstrate one mechanism that helps to explain this
finding in APL.

2.3 Results
Constitutive loss of Dnmt3a leads to canonical, locus-specific DNA hypomethylation in
hematopoietic cells
For the studies of Dnmt3a deficiency in this report, we utilized a constitutive Dnmt3a
knockout mouse that contains a deletion of part of the catalytic methyltransferase
domain of the Dnmt3a enzyme (26). We verified that this allele is a true null for Dnmt3a
protein (Supplemental Figure S1A), and that Dnmt3a RNA expression is dramatically
reduced, with no effects on neighboring genes (data not shown, and see below). Since
constitutive Dnmt3a-/- mice die of severe runting at about three weeks of age (26), we
harvested the bone marrow cells from wild-type (WT) or Dnmt3a-/- mice at 2.5 weeks of
age, and transplanted them into lethally irradiated C57Bl/6 recipients to study the effects
of Dnmt3a loss on hematopoiesis. These mice were allowed to engraft for eight weeks,
and were then harvested for morphologic examination, flow cytometry, and DNA
methylation studies. Importantly, there were no detectable perturbations in the
populations of the stem/progenitor cells or mature cells of any lineage in the engrafted
marrow from the Dnmt3a-/- donors (see below). Bone marrow cells from three WT and
three Dnmt3a-/- mice were subjected to CpG-capture and bisulfite sequencing. The
targeted genomic regions included all annotated CpG islands, as well as areas of the
genome that have been previously established to exhibit differential patterns of
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methylation in different tissues, and other regulatory DNA sequences such as
enhancers and insulators (Supplemental Table S1). The coverage data for each
sample is shown in Supplemental Table S2.

All three Dnmt3a-/- bone marrow samples displayed a global decrease in highly
methylated CpGs, and a corresponding increase in CpGs that were unmethylated
(Supplemental Figure S1B). Nearly all of the CpGs that were differentially methylated
were hypomethylated in the Dnmt3a-/- samples (231,001 hypomethylated CpGs, vs.
5,488 that were more methylated in Dnmt3a-/- samples, Supplemental Figure S1C). This
hypomethylation phenotype is in general agreement with previously published studies
using a conditional Dnmt3a knockout mouse, where the CpGs from purified stem cell
and B cell populations of serially transplanted mice were predominantly hypomethylated
(3, 27).
Nearly all of the 5,000 most differentially methylated CpGs were hypomethylated in all
three Dnmt3a-/- samples (Supplemental Figure S1D), and most of the canonically
hypomethylated CpGs occurred in defined genomic regions (3, 27). For example, a
region on chromosome 16 near the internal (P2) promoter of the Runx1 gene contains a
“canyon” that is completely unmethylated in both WT and Dnmt3a-/- bone marrow cells
(Supplemental Figure S1E) (27). This canyon is flanked on both sides by regions that
are highly methylated in wild-type bone marrow cells, but essentially unmethylated in
Dnmt3a-/- bone marrow cells.
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These results establish that this Dnmt3a deficient mouse strain has a strong focal
hypomethylation phenotype in hematopoietic cells, credentialing it for these studies. A
complete description of the methylation and expression phenotypes of the bone marrow
cells of these mice will be presented elsewhere (Ketkar et al., unpublished
observations).

Dnmt3a is required for aberrant self-renewal induced by PML-RARA, but is dispensable
for self-renewal caused by RUNX1-RUNX1T1 and MLL-AF9.
We next asked whether Dnmt3a deficiency influenced aberrant self-renewal induced by
the AML fusion genes RUNX1-RUNX1T1, MLL-AF9, and PML-RARA. These
oncogenes are capable of inducing an aberrant self-renewal phenotype ex vivo when
expressed in wild-type mouse bone marrow cells with retroviral vectors (13, 28-29).
Whole bone marrow cells, when transduced with MSCV viruses containing cDNAs for
RUNX1-RUNX1T1, MLL-AF9, or PML-RARA, and then plated in semi-solid MethoCult
media, form CFU-GM (Colony-Forming Unit, Granulocyte-Monocyte) colonies that
express CD11b (a marker of terminally differentiated myelomonocytic cells). Progenitor
cells from these transductions can be serially replated for several weeks. Wild-type
bone marrow cells do not serially replate in this assay, losing the ability to form new
myeloid colonies containing cells that express CD11b after one week. To test whether
self-renewal in this assay was dependent on Dnmt3a, we harvested whole bone marrow
cells from 2-2.5 week old WT or Dnmt3a-/- littermates, and transduced them with MSCV
viruses containing either an empty vector with an IRES-YFP cassette, or with viruses
that contain cDNAs for RUNX1-RUNX1T1, MLL-AF9, or PML-RARA (and an IRES-YFP
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cassette to identify the transduced populations). Transduced cells were plated in
MethoCult media (Figure 1A). Each week, colonies were quantified, and cells were
assessed for expression of CD11b by flow cytometry, and then cells were replated.
Both WT and Dnmt3a-/- bone marrow cells transduced with “empty” control YFP vector
lost the ability to form colonies after one or two replating cycles (Figure 1B). In contrast,
both WT and Dnmt3a-/- bone marrow transduced with either MLL-AF9 or RUNX1RUNX1T1 gave rise to increasing numbers of colonies over time (Figure 1C-D). In
contrast, the PML-RARA expressing virus could induce serial replating in WT but not
Dnmt3a-/- derived marrow cells (Figure 1E). Both WT and Dnmt3a-/- bone marrow
transduced with either the MLL-AF9 or RUNX1-RUNX1T1 viruses maintained
expression of the myeloid marker CD11b after three replatings; in contrast, CD11b
expression was maintained in WT bone marrow transduced with PML-RARA, but lost in
the absence of Dnmt3a (Figure 1 F-G). Additional flow cytometry and morphologic
examination demonstrated that the few remaining cells at week three in the Dnmt3a-/marrow transduced with PML-RARA were FcεR positive, c-kithigh mast cells, similar to
cells transduced with the empty vector GFP (data not shown). Together, these results
indicate that in a retroviral transduction system, aberrant myeloid self-renewal by PMLRARA requires Dnmt3a, whereas self-renewal driven by MLL-AF9 or RUNX1-RUNX1T1
does not.

Dnmt3a is required for the aberrant self-renewal of hematopoietic progenitor cells from
Ctsg-PML-RARA mice.
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To orthogonally validate these results, we crossed Dnmt3a+/- mice to a wellcharacterized PML-RARA-expressing transgenic mouse model created in our laboratory
(Ctsg-PML-RARA, hereafter called PR+/-) (12), to ultimately generate PML-RARA
expressing mice lacking both copies of Dnmt3a (PR+/-, Dnmt3a-/-) as well as all relevant
control genotypes (WT, Dnmt3a-/-, and PR+/-).

Ctsg-PML-RARA mice express a human PML-RARA fusion gene under control of the
endogenous mouse Cathepsin G locus, which leads to PML-RARA expression in early
myeloid progenitor cells (with highest expression levels in GMPs, where dysregulation
of target genes is most pronounced) (30), and the development of lethal acute
promyelocytic leukemia (APL) with long latency and high penetrance (~60% at one year
in C57Bl/6 mice) (12). Bone marrow cells derived from these mice display an
advantage with competitive transplantation, and give rise to self-renewing myeloid
progenitors on semi-solid medium ex vivo (30). We reasoned that if functional Dnmt3a
were required for any of these aberrant self-renewal phenotypes, they would be
abrogated in PR+/-, Dnmt3a-/- mice.
We first measured PML-RARA expression (by qRT-PCR) in bone marrow cells derived
from wild-type, PR+/-, and PR+/-, Dnmt3a-/- mice (Figure 2A), to determine whether
Dnmt3a deficiency altered the expression of PML-RARA. No PML-RARA transcripts
were detected in wild-type bone marrow cells, confirming the specificity of this assay
(30). The level of PML-RARA expression was not reduced by Dnmt3a deficiency, and
was in fact slightly higher than in PR+/- mice.
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We next assessed the engraftment and differentiation potential of Dnmt3a-/- vs. PR+/-,
Dnmt3a-/- donor cells (compared to WT and PR+/- donor cells) by harvesting whole bone
marrow from 2-2.5 week old littermates from all four genotypes, and transplanting these
cells into lethally irradiated wild-type recipients. After 8-10 weeks, the engrafted bone
marrow cells from all donor genotypes were assessed for their contributions to myeloid
and lymphoid lineages (Figure 2B). There was no significant difference in the
proportion of mature myeloid (Gr-1+ and/or Cd11b+) or mature lymphoid (B220+ or
CD3+) cells regardless of Dnmt3a status. Similarly, there were no differences in the
numbers of stem and progenitor cells in recipients of marrow with or without Dnmt3a
(Figure 2C). At 16 weeks post-transplant, no differences were observed in numbers of
peripheral blood leukocytes, red blood cells, or platelets, regardless of the presence or
absence of Dnmt3a (Supplemental Figure S2A). Histologic examination of the bone
marrow cells of engrafted recipients demonstrated normal cellular morphology with no
evidence of dysplastic changes (data not shown). Collectively, these data demonstrate
that Dnmt3a loss does not lead to impaired engraftment or grossly altered steady-state
hematopoiesis for at least four months after transplantation into wild type recipient mice.

We next tested whether ex vivo self-renewal was directly altered in bone marrow cells
derived from 2-2.5 week old mice from all genotypes (i.e. not transplanted, Figure 2D).
WT cells lost the ability to form colonies after one or two replatings, whereas PR+/marrow gave rise to increasing numbers of colonies with serial replating. PR+/-,
Dnmt3a-/- cells gave rise to similar numbers of colonies as WT and PR+/- with the first
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and second platings, but failed to replate thereafter. PR+/- cells maintained expression
of CD11b with serial replating (Figure 2E). In contrast, replated PR+/-, Dnmt3a-/- cells
lost expression of CD11b by the end of the second week (Figure 2E-F). We also tested
whether this phenotype was intrinsic to the hematopoietic compartment (as opposed to
an effect from Dnmt3a-/- stromal cells) by transplanting bone marrow from young (2 to
2.5-week-old) mice into lethally irradiated wild-type C57Bl/6 recipients, and harvesting
marrow for replating assays at ten weeks post-transplant (Supplemental Figure S2B).
As expected, bone marrow derived from the recipients of PR+/- donors formed colonies
with serial replating, whereas bone marrow derived from PR+/-, Dnmt3a-/- donors did not
(Supplemental Figure S2C). These data demonstrate that this phenotype is due to a
cell-autonomous defect in the hematopoietic compartment.

Dnmt3a deficiency attenuates the expression of genes that are normally upregulated by
PML-RARA in Granulocyte Monocyte Progenitor cells (GMP cells)
To determine whether Dnmt3a loss affects genes that are specifically dysregulated by
PML-RARA, we analyzed the expression of genes previously shown to be differentially
expressed between WT and Ctsg-PML-RARA (PR+/-) mice (30). In that study, we
observed that these genes show the greatest differences in the GMP compartment of
PR+/- mice, where Ctsg is maximally expressed: 112 probesets from the Affymetrix
mouse exon ST1.0 arrays were significantly upregulated by PML-RARA in an ANOVA
analysis (fold change ≥2.0, FDR <0.05), and 127 probesets were downregulated (30).
We therefore performed expression profiling using purified GMP cells from the
engrafted marrows of several donor mice from all four genotypes (WT n=4; PR+/- n=2;
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PR+/-, Dnmt3a-/- n=4; and Dnmt3a-/- n=3) harvested 6-8 weeks after transplantation. The
results of these analyses are highly concordant with the results of Wartman et al. Of the
112 upregulated probesets (designated as the PR+/-a dataset in Figure 3), 96 (86%)
exhibited a similar ≥2 fold increase in expression in the data obtained for this study
(denoted as the PR+/-b dataset, Figure 3, Panel A, and Supplemental Table S3). The
average fold change (comparing WT to PR+/- ) for this set of probes in the PR+/-a dataset
was 8.52 +/- 1.10 (SEM), which was not significantly different from the average fold
change of the same genes in the PR+/-b dataset (8.71 +/- 1.11; p=0.75; Figure 3A, left
panel). GMP cells from the PR+/-, Dnmt3a-/- mice demonstrated significantly less
upregulation of many of these probes: the average fold change was 6.24 +/- 0.66 (p =
9.73E-06 compared to PR+/-b); these data suggest that Dnmt3a loss attenuates the
expression of a set of genes that are normally upregulated by PML-RARA in GMP cells.
Of the 127 probes that were downregulated at least two-fold in the PR+/-a dataset, 107
(84%) were likewise downregulated in the PR+/-b dataset, but to a lesser extent (Figure
3, Panel A, right). The average level of downregulation was only -2.91 fold for the PR+/-a
dataset, and -1.71 fold for the PR+/-b dataset. The average expression of these
downregulated genes was not appreciably attenuated by Dnmt3a loss, perhaps
because the fold changes were relatively small, and therefore more difficult to detect. A
heatmap of probeset level data is shown for the 239 dysregulated probes defined by the
PR+/-a dataset (Figure 3, Panel B), plotting only the average values for the data
generated in this study from mice with the designated genotypes. These data extend
the fold change data shown in Panel A, and demonstrate that a large number of PR+/dysregulated probesets are affected by Dnmt3a loss. As expected, GMP cells from
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Dnmt3a-/- mice had very few changes in expression of the genes that are canonically
dysregulated by PML-RARA. We also independently defined differentially expressed
genes from the four genotypes using only the data from this study (Supplemental Figure
S3, Supplemental Table S4). As expected, this data corroborated the Wartman et al.
(30) study for the PR+/- dysregulated genes, and identified Dnmt3a itself as one of the
most downregulated genes in the Dnmt3a-/- and PR+/-, Dnmt3a-/- GMP cells. The
expression signature for Dnmt3a deficient GMP cells was subtle and limited to very few
probesets, which is consistent with other studies of both mouse and human
hematopoietic cells with reduced or absent Dnmt3a expression (1, 2, 3, 5).

DNA methyltransferase activity of DNMT3A is required for aberrant self-renewal by
PML-RARA ex vivo.
Both DNMT3A and the highly homologous enzyme DNMT3B are known to possess de
novo DNA methyltransferase activities (31). The most common DNMT3A mutations in
AML occur at residue R882 (2). DNMT3A possessing the R882H mutation has been
shown to exhibit reduced DNA methyltransferase activity and produce a dominant
negative effect against WT DNMT3A, which leads to a focal DNA hypomethylation
phenotype in primary AML samples (6). Some other mutations, such as the Q615*
mutation, introduce a premature stop codon that is predicted to form a truncated protein
lacking the entire C-terminal methyltransferase domain (Figure 4A) (2). However,
DNMT3A has also been reported to influence gene expression by interacting with and
stabilizing a co-repressive complex, in a manner that is independent of its
methyltransferase activity (32). To determine whether the DNA methyltransferase
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activity of DNMT3A is necessary for PML-RARA functions, we conducted
complementation experiments where PR+/-, Dnmt3a-/- cells were transduced with
retroviruses containing either full-length WT human DNMT3A, full-length DNMT3A with
the R882H mutation, the Q615* truncation mutant, or an empty IRES-YFP vector
control. We verified that all constructs were expressed in PR+/-, Dnmt3a-/- bone marrow
cells that were sorted for transduced (YFP+) cells using western blotting with an
antibody against the N-terminus of DNMT3A (Figure 4B). All proteins were highly
expressed, and migrated at their predicted sizes on SDS-PAGE. When sorted YFP+
cells were plated in MethoCult medium, PR+/-, Dnmt3a-/- cells transduced with the empty
YFP vector ceased to produce colonies by week four. Reintroduction of wild-type
DNMT3A was able to restore both colony formation (Figure 4C) and CD11b expression
(Figure 4D-E). However, neither of the two mutants known to be deficient for DNA
methyltransferase activity (DNMT3A R882H and DNMT3A Q615*) was able to restore
replating ability (Figure 4C), or expression of CD11b (Figure 4D-E).
We also asked whether WT DNMT3A was able to restore the normal methylation of a
subset of CpG residues in the Runx1 P2 promoter region shown in Supplemental Figure
S1E (green numbers 1-4 shown above the gene). We developed a set of PCR
amplicons that each contained a single site for the methylation-sensitive restriction
endonuclease HpaII (i.e. a single assayable CpG residue, see Supplemental Table S5).
We obtained DNA from the bone marrow cells of PR+/-, Dnmt3a+/- mice transduced with
empty YFP, wild-type DNMT3A, or the catalytically impaired DNMT3A mutants, and
cultured the transduced YFP+ cells in MethoCult media for six or seven days. DNA
harvested from these cells (and appropriate control mice) was then digested to
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completion with HpaII, and qPCR was performed to assess the total level of HpaII
cleavage within each amplicon (as a surrogate for the level of cytosine methylation at
that particular CCGG cleavage site). Compared to WT or PR+/- derived cells, PR+/-,
Dnmt3a-/- cells transduced with empty YFP displayed near complete hypomethylation at
site 1 (shown in Figure 4F) and site 2 (Supplemental Figure S4B) within the Runx1 P2
promoter region. Reintroduction of wild-type DNMT3A, but not the R882H or Q615*
mutants, restored a nearly normal level of methylation to these two sites after only one
week, a time frame corresponding to the rapid reintroduction of self-renewal by
expression of wild-type DNMT3A. Sites 3 and 4, in the hypomethylation “canyon” that is
normally unmethylated in bone marrow cells, did not display remethylation with
overexpression of DNMT3A for one week (Supplemental Figure S4A-C); these controls
demonstrate that HpaII was capable of cleaving unmethylated sites in these DNA
samples, and that the overexpression of DNMT3A did not cause abnormal methylation
of CpGs that are not normally methylated. Together, these results strongly suggest that
it is the DNA methyltransferase activity of DNMT3A per se that is required for PMLRARA to drive aberrant self-renewal in myeloid progenitor cells.

Dnmt3b is dispensable for the aberrant self-renewal ability of PML-RARA mouse bone
marrow ex vivo.
DNMT3B exhibits different sequence specificity from DNMT3A in vitro (33), but ChIPseq studies have demonstrated extensive overlap in the genomic regions bound by
DNMT3A and DNMT3B in vivo (34). To determine whether PML-RARA also requires
Dnmt3b for its ability to induce self-renewal, we generated PR+/- mice that were null for
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the Dnmt3b allele in bone marrow cells. Because Dnmt3b loss leads to embryonic
lethality, we crossed mice with floxed Dnmt3b alleles (35) to mice expressing the panhematopoietic Vav1-Cre transgene (36) to generate animals with a selective loss of
Dnmt3b in hematopoietic cells. This conditional null allele of Dnmt3b has previously
been demonstrated to result in no production of Dnmt3b protein by western blot analysis
(37). We intercrossed these three strains of mice to generate PR+/-, Dnmt3b flox/flox
mice with or without Vav1-Cre (PR+/-, Dnmt3b flox/flox, Vav1-Cre+, vs. PR+/-, Dnmt3b
flox/flox, Vav-Cre-), and then compared the ability of bone marrow cells from these mice
to self-renew ex vivo, as described above (Figure 5A). Importantly, total bone marrow
cells from Dnmt3b flox/flox, Vav1-Cre+ mice demonstrated >95% floxing efficiency of
Dnmt3b (data not shown), and had a focal hypomethylation phenotype that was
overlapping but distinct from that of Dnmt3a deficient mice (7, and Ketkar et al.,
unpublished observations). Dnmt3b was not required for PML-RARA to drive selfrenewal, since PR+/-, Dnmt3b flox/flox marrow could be serially replated, and formed
equal numbers of colonies regardless of the presence or absence of Cre-mediated
Dnmt3b excision (Figure 5B). In addition, Dnmt3b loss was essentially dispensable for
maintaining CD11b expression with serial replating (Figure 5C), although PR+/-, Dnmt3b
flox/flox, Vav-Cre+ positive cells did display a slight decrease in CD11b positivity that
was statistically significant over time (Figure 5D). We also performed a
complementation experiment by transducing PR+/-, Dnmt3a-/- bone marrow cells with a
retrovirus expressing a full-length wild-type human DNMT3B cDNA (Figure 5E and
Supplemental Figure S5). Overexpression of DNMT3B was unable to restore colony
formation (Figure 5F). These results reinforce the hypothesis that the requirement of
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PML-RARA for DNMT3A is specific for the methyltransferase activity of this protein, and
it cannot be replaced by DNMT3B.

Dnmt3a is dispensable for leukemia induction by MLL-AF9
The replating results shown above revealed that aberrant self-renewal by MLL-AF9 and
RUNX1-RUNX1T1 did not require Dnmt3a. We next tested whether MLL-AF9 leukemia
induction was Dnmt3a-independent in vivo. We expressed MLL-AF9 cDNA in WT or
Dnmt3a-/- bone marrow cells via retroviral transduction, and then transplanted these
cells into lethally irradiated wild-type recipients (Figure 6A). This retroviral model of
MLL-AF9 produces a rapid onset, high-penetrance AML (29). At four weeks posttransplant, recipients of MLL-AF9 transduced bone marrow exhibited elevated white
blood cell counts regardless of the genotype of the transduced donor cells (Figure 6B),
and shortly thereafter succumbed to AML (Figure 6C) with identical latency, similar
degrees of splenomegaly (Figure 6D) and 100% penetrance (Figure 6E). There were
no detectable phenotypic differences between the leukemias that arose in WT vs.
Dnmt3a-/- bone marrow.

Dnmt3a is required for PML-RARA-driven competitive advantage and APL development
in vivo
Previous studies using a conditional Dnmt3a deficient mouse model revealed a
progressive deficit in hematopoietic maturation in serial competitive transplants (3). In
contrast, PR+/- derived bone marrow cells have a competitive transplantation advantage,
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as demonstrated by an increased ability to contribute to peripheral blood lineages
(especially myeloid) over time (38). To determine whether Dnmt3a is required for this
competitive advantage, we mixed whole bone marrow cells from mice with the indicated
genotypes (Figure 7A) in an equal ratio with wild-type competitor marrow, and
transplanted the cells into lethally irradiated wild-type mice. Serial analyses of
peripheral blood at four week intervals confirmed that PR+/- bone marrow is able to
outcompete wild-type marrow over time, with 72 +/- 3.7% (SEM) of all peripheral blood
cells being derived from PR+/- donor marrow at 16 weeks after transplantation (Figure
7B). Dnmt3a loss eliminated this competitive advantage, leading to 33.2 +/- 8.6% and
28.7 +/- 7.8% of peripheral blood cells derived from Dnmt3a-/- or PR+/-, Dnmt3a-/- donor
marrow cells, respectively. To determine whether this reflected a defect in
peripheralization rather than a true competitive disadvantage, we sacrificed animals six
months post-transplant and examined donor-derived cells from each genotype in the
bone marrow and spleen (Figure 7C). The competitive advantage for PR+/- derived cells
was evident in both of these tissues, with 73.4 +/- 6.4% of bone marrow cells and 67.2
+/- 3.6% of spleen cells derived from PR+/- derived donor cells. In contrast, cells derived
from PR+/-, Dnmt3a-/- mice comprised only 38.2 +/- 12.8% of total bone marrow cells and
25.9 +/- 7.3% of total spleen cells, with similar competitive deficits observed in the
marrow from the Dnmt3a-/- donors.
Dnmt3a loss has been shown to have effects at the level of long-term hematopoietic
stem cells (3, 39) but PML-RARA is primarily expressed in multipotent progenitors and
myeloid progenitors in Ctsg-PML-RARA mice (30). We therefore performed additional
experiments comparing recipients of PR+/- versus PR+/-, Dnmt3a-/- marrow to determine
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whether Dnmt3a loss in this model might negatively affect the ability of HSPCs to
differentiate into more committed progenitors. We evaluated donor-derived long-term
HSCs (as well as more committed progenitor populations), and calculated the lineage
bias for each genotype, defined as the ratio of donor-derived cells of a given population
(e.g. the percentage of long-term HSCs) to the total percentage of donor-derived cells
(percentage of Ly5.2+ cells). The expected ratio is 1:1 for cells contributing equally to
all lineages. Despite an overall competitive disadvantage (compared to PR+/- donor
cells), PR+/-, Dnmt3a-/- donor cells were twice as likely to contribute to long-term HSCs
(Figure 7D), p<0.001, two-way ANOVA. In agreement with previous experiments using
conditional Dnmt3a-/- mice (3, 39), the ratio of contributions to other downstream
populations (such as short-term-HSC, GMP, and CMP) was not different among the
genotypes (Figure 7E). Collectively, these results suggest that Dnmt3a is required for
the competitive advantage provided by PML-RARA, perhaps by acting upstream from
the myeloid progenitor cells that PML-RARA ‘reprograms’.

To determine whether Dnmt3a is required for PML-RARA to induce APL in vivo, we
transplanted bone marrow from 2-2.5 week old PR+/- or PR+/-, Dnmt3a-/- animals into
lethally irradiated wild-type recipients as described in Figure 2A, and performed a longterm tumor watch. Within one year of transplantation, 6/16 PR+/- mice developed the
typical features of APL, including splenomegaly, an abnormal proliferation of mature
myeloid cells, and atypical promyelocytes in the bone marrow and blood, as previously
described (12). In contrast, 0/13 PR+/-, Dnmt3a-/- animals developed APL during the
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same period of observation (Figure 7D, p<0.05 by both Mantel-Cox and GehanBreslow-Wilcoxon tests).
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2.4 Discussion
In this report, we have explored mechanisms underlying the mutual exclusivity of AMLinitiating fusion genes and mutations in DNMT3A, both of which are common in AML
patients. Although retroviral expression of RUNX1-RUNX1T1 or MLL-AF9 induced selfrenewal regardless of Dnmt3a status, PML-RARA required Dnmt3a to induce selfrenewal ex vivo. Dnmt3a was likewise required for the self-renewal of myeloid
progenitor cells derived from Ctsg-PML-RARA mice, and also their ability to outcompete wild-type progenitors in a competitive transplant model. We demonstrated that
aberrant self-renewal ex vivo is specifically dependent on the DNA methyltransferase
activity of DNMT3A, since neither DNMT3B nor mutant DNMT3A genes from AML
patients that are deficient in catalytic activity were able to restore myeloid self-renewal.
Reintroduction of wild-type human DNMT3A was able to restore normal DNA
methylation to a canonically hypomethylated locus, and restore aberrant self-renewal
ability. Finally, Ctsg-PML-RARA mice that were deficient for Dnmt3a had a reduced
penetrance of APL in vivo.

PML-RARA confers an aberrant self-renewal activity to myeloid progenitors, a finding
that is evident long before the development of overt leukemia (30, 38, 40). This property
allows myeloid progenitor cells to be serially replated ex vivo, and to out-compete wildtype progenitors in competitive transplants (30,38). Aberrant self-renewal may be an
essential feature of AML pathogenesis; this phenotype may increase the likelihood that
additional, cooperating mutations will occur in cells with increased self-renewal
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potential. Our findings demonstrate that functional Dnmt3a is required for both the in
vivo and ex vivo myeloid self-renewal phenotypes induced by PML-RARA.

The hematopoietic phenotype we demonstrate for PR+/-, Dnmt3a-/- marrow displays both
similarities and differences from the previously reported phenotypes in serially
transplanted hematopoietic cells derived from conditional Dnmt3a deficient mice. Like
Challen et al. (3), we observed a differentiation bias towards self-renewal in Dnmt3a-/long-term HSCs. However, we found that loss of Dnmt3a decreased the competitive
engraftment ability of progenitors derived from the marrow of PR+/- mice. We used
whole bone marrow in our study, because it was designed to recapitulate our previous
studies (30) that demonstrated that whole bone marrow cells from PR+/- mice display a
competitive advantage in vivo. There are numerous methodological differences
between the two studies, including the use of unfractionated marrow and a single
transplantation event in our studies, versus the use of sorted long-term stem cells and
serial transplantation in the previous study, which may partially explain apparent
discrepancies.

Mayle et al. (39) have shown that sorted hematopoietic stem cells from conditional
Dnmt3a deficient mice have an increased propensity to develop both myeloid and
lymphoid malignancies after a long latent period, whereas in this study, Dnmt3a
deficiency protected Ctsg-PML-RARA mice from developing APL. Further, our PR+/-,
Dnmt3a-/- mice did not spontaneously develop other forms of AML or ALL. In this study,
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we transplanted whole bone marrow rather than purified hematopoietic stem cells, the
number of animals at risk was small (n=13), and the study was terminated when
significance was achieved at one year. It is therefore possible that some of these mice
could have developed alternative hematopoietic malignancies had they been followed
for a longer period of time. We did not perform an independent tumor watch using the
germline Dnmt3a-/- mice, so we do not yet know whether there are biologically relevant
differences between these two different Dnmt3a deficient models, or whether
differences in phenotypes result from the methodological differences described above.
Additional studies will be required to better understand the differences between these
model systems.

Dnmt3a was not required for the aberrant ex vivo self-renewal induced by two common
AML-initiating fusions, RUNX1-RUNX1T1 and MLL-AF9, and was not required for MLLAF9 to induce AML in vivo. This data strongly suggests that Dnmt3a loss does not
cause a general state of hematopoietic dysfunction that is incompatible with the
development of AML. In fact, previous studies have shown that Dnmt1 (but not Dnmt3a
or Dnmt3b) is highly expressed in a putative leukemic stem cell population from MLLAF9 expressing AML cells (L-GMP) (41,42). In this model, haploinsufficiency for Dnmt1
delayed leukemia progression, suggesting that MLL-AF9 requires maintenance
methylation by Dnmt1 for the induction of leukemia, rather than de novo DNA
methylation by Dnmt3a or Dnmt3b. Likewise, RUNX1-RUNX1T1 has been reported to
recruit DNMT1 and histone deacetylases in order to silence gene expression,
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suggesting that it also may require Dnmt1 to induce leukemia in mice, instead of
Dnmt3a (43,44).

We have shown that Dnmt3a deficiency attenuates the upregulation of several genes
that are normally dysregulated by PML-RARA expression in GMP cells. Additional
studies will be necessary to determine the specific genes and pathways that PMLRARA uses to drive aberrant self-renewal, and how these pathways are affected by
DNMT3A. Previous studies have suggested that PML-RARA recruits DNMT3A to
induce DNA methylation at specific sites in the genome, resulting in the repression of
gene expression (18, 20, 23). However, alternative hypotheses have also been
proposed: a recent study has suggested that PML-RARA binding to DNA may actually
protect target sites from CpG methylation; these findings argue that the characteristic
methylation changes of APL cells are not actually required for initiation of APL, but
rather occur after transcription factors leave key binding sites (45, 46).

Neither DNMT3B nor catalytically inactive mutants of DNMT3A were capable of
restoring replating to PR+/-, Dnmt3a-/- marrow. This specific requirement for Dnmt3a
may be due to the fact that the two enzymes have different sequence specificities in
vitro (33,47) and have been shown to act on overlapping but distinct genomic regions in
vivo (5,34). Therefore, Dnmt3a-specific methylation patterns may be required for PMLRARA to induce leukemia.
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Collectively, these results suggest an important role for DNMT3A in the development of
APL: PML-RARA appears to specifically require DNMT3A to initiate the self-renewal
phenotype in myeloid progenitor cells. These findings have helped to define a
mechanistic relationship between two recurrent but independent AML driver mutations,
and add to the growing body of evidence implicating epigenetic changes in the induction
of AML.

59

2.5 Methods
Mice
The Ctsg-PML-RARA and Dnmt3a-/- mice have previously been described (12, 26). Both
strains have been backcrossed to C57Bl/6 mice for more than ten generations.
Dnmt3a+/- mice were obtained from the Mutant Mouse Regional Resource Centers
repository (MMRRC Strain Name B6.129S4-Dnmt3atm2Enl/Mmnc). PR+/-, Dnmt3a-/- mice
and all control genotypes were produced by intercrossing PR+/-, Dnmt3a+/- mice.
Dnmt3b flox/flox mice in the B6 background (B6.129S4(Cg)‐Dnmt3btm5.1Enl/Mmnc)
were obtained from the Mutant Mouse Regional Resource Center at UNC. Vav1-Cre
mice in the B6 strain were obtained from the Jackson Laboratory (B6.CG-TG(VAV1CRE)A2KIO/J). Whenever possible, littermate controls were used for all experiments. .
Bone Marrow Harvest and Transplantation
Bone marrow was harvested from femurs, tibias, pelvi, and humeri of 2 to 2.5-week-old
mice. After lysis of red blood cells (ACK buffer: 0.15 M NH4Cl, 10 mM KHCO3, 0.1 mM
Na2EDTA), cells were washed with FACS buffer, filtered through 50-μm cell strainers
(Partec) and resuspended in PBS at 1 million cells/100 uL for transplantation. For
competitive transplant experiments, bone marrow was mixed 50:50 with freshly
harvested cells from 6-week-old Ly5.1 mice (The Jackson Laboratory, Bar Harbor, ME).
Transplantation was performed by retro-orbital injection of 1 × 106 total bone marrow
cells into lethally irradiated Ly5.2 or Ly5.1x5.2 recipients that had received 2 split doses
of 550 cGy total body irradiation spaced at 4 hours (Mark 1 Cesium-137 irradiator, JL
Shepherd) 24 hours prior to transplantation.
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Mouse Analysis and Tumor Watch
Peripheral blood counts were assessed at regular intervals as indicated by automated
CBC (Hemavet 950, Drew Scientific Group). For long-term tumor watch experiments,
bone marrow transplant recipients were monitored daily and animals displaying signs of
illness (lethargy, hunched posture, ruffled fur, dyspnea, or pallor) were euthanized and
spleen and bone marrow harvested for analysis. Diagnosis of leukemia was made by
light microscopic examination of spleen and/or peripheral blood cells according to the
Bethesda criteria (48) and previously published phenotyping of the Ctsg-PML-RARA
and MLL-AF9 viral transduction mouse models. Cytospin tissue slides were stained
with Wright-Giemsa stain (Sigma-Aldrich) and were imaged using a Nikon
MICROPHOT-SA microscope equipped with an oil-immersion 50×/0.90 or 100×/1.30
objective lens (Nikon Corp.) The tumor watch was terminated at one year posttransplantation.

MSCV Vectors
Full-length human DNMT3A (NM_175629) and DNMT3B (NM_006892) cDNAs
(Origene) were cloned into MSCV IRES YFP or MSCV IRES GFP (Addgene) using
PCR-introduced EcoRI restriction digest sites and standard ligation techniques.
DNMT3A R882H and Q615* mutations were introduced using QuikChange II XL
mutagenesis kit (Agilent). PML-RARA cDNA was prepared from the BCR3 PML-RARA
cDNA used to create the Ctsg-PML-RARA mouse and cloned into MSCV-IRES-YFP as
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described above. MSCV MLL-AF9-IRES-GFP and MSCV RUNX1-RUNX1T1-IRESGFP vectors were the kind gifts of Dr. Andy Lane. Virus was produced using cotransfection of MSCV vector and EcoPak packaging plasmid (Addgene) into 293T cells,
using standard calcium-phosphate transfection, and then harvested at 48 hours posttransfection and stored at -80°C. For transduction of mouse bone marrow, marrow was
harvested as above and plated overnight in transplant media containing RPMI +15%
FBS + SCF (100 ng/mL), Il-3 (10 ng/mL), FLT-3 (50 ng/mL) and TPO (10 ng/mL). All
cytokines were purchased from PeproTech. Cells were transduced by spinfection at
2500 RPM for 90 minutes at 30 degrees in transplant media with the addition of 1M
HEPES Buffer/0.85% sodium chloride supplemented with polybrene (10 ug/mL,
American Bioanalytical). After two rounds of spinfection, GFP- or YFP-positive cells
were sorted using an I-Cyt Synergy II sorter (I-cyt Technologies) and plated in
methocellulose for colony formation assays.

Methylcellulose Colony Formation Assay
10,000 cells per plate were plated in triplicate in M3534 MethoCult media containing Il3, Il-6, and SCF (Stem Cell Technologies) and incubated at 37°C for one week. Each
week, clusters of cells meeting the morphologic criteria for CFU-GEMM, CFU-GM, CFUG, or CFU-M
(http://www.stemcell.com/~/media/Technical%20Resources/8/3/E/9/0/28405_methocult
%20M.pdf?la=en) were counted as myeloid colonies and cells were lifted using warm
DMEM media + 2% FBS, spun down, and replated as before. An aliquot of cells was
taken for analysis of myeloid markers by flow cytometry.
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Methylation Capture Sequencing
Whole bone marrow was isolated from 2 to 2.5-week-old mice (n=3 per genotype) and
transplanted into lethally irradiated wild-type mice and allowed to stably engraft for 8-10
weeks before whole marrow was harvested and DNA isolated using QiaAmp DNA Mini
Kit (Qiagen). 12 ug of input DNA from each sample was processed with the
SureSelectXT Methyl-Seq Target Enrichment System for the Illumina Multiplexed
Sequencing protocol (Agilent Technologies, Santa Clara, CA). DNA was subsequently
fragmented using a Covaris S2 (Covaris Inc., Woburn, MA) with the following settings:
Duty Cycle: 10%, Intensity: 5, Cycles per Burst: 200, Cycles: 6, Time/Cycle: 6 seconds.
Library preparation followed the SureSelect Methyl-Seq Library Prep Kit (Agilent
Technologies, Santa Clara, CA) with minor modifications. After end-repair, the DNA
was purified using Ampure-XP kit (Beckman-Coulter, Brea, CA) and was recovered in
80µL 10mM Tris-HCl, pH 7.8. Samples were subsequently divided into four A-tailing
and adapter ligation reactions following the manufacturer’s recommendations for 3µg of
input DNA. Post-ligation, all four reactions for each sample were pooled and processed
for hybridization using the SureSelect Methyl-Seq Target Enrichment and Methyl-Seq
Hybridization Kits (Agilent Technologies, Santa Clara, CA). In the hybridization
reactions, we combined the SureSelect Indexing Block #1 and #2 oligonucleotides with
5µg of Mouse Cot-1 DNA (Invitrogen, Carlsbad, CA). The hybridized probe:library
fragment duplexes were immobilized with streptavidin-bound paramagnetic M280
particles (Invitrogen, Carlsbad, CA). The hybridized (captured) ssDNA library fragments
were eluted from their duplexes and neutralized using the supplied elution and
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neutralization buffers, respectively. The methyl-captured fragments were bisulfiteconverted using the DNA Methylation Gold Kit (Zymo Research, Irvine, CA), and the
converted ssDNA library fragments were amplified, 8 cycles, with non-indexed primers
as described in the manufacturer’s protocol. A subsequent amplification incorporated
library-specific index sequences during the PCR. The final library amplifications were
treated with 0.8:1.0 ratio for AmpureXP beads-to-DNA, eluted with 20µl 10mM Tris-HCl
(pH 7.8), quantified by Qubit (Invitrogen, Carlsbad, CA), and sized with the DNA 1000
Chip Kit (Agilent Technologies, Santa Clara, CA) for a molarity determination. All four
samples were diluted to 5nM, assayed by qPCR, and based on qPCR results diluted to
a 2nM solution. Each 2nM sample was mixed at equal volumes, and the 2nM pool was
sequenced, 2x100 bp, across four lanes of an Illumina HS2000 flow cell using V3
chemistry. BSMAP version 1.037 was used to align the bisulfite sequencing reads.
Methylation ratios per base were calculated via methratio.py script. The methylation
ratios were read into Methylkit package in R to generate coverage and methylation
statistics, sample correlation, clustering, and differential methylation analysis. The
datasets for the CpG-capture experiments are deposited in the Short Read Archive, with
accession number PRJNA283621; the Superseries ID that links the methylation and
expression data for this study is Umbrella BioProject PRJNA284138.

Expression profiling
Expression array profiling was performed exactly as described (30). Labeled RNA
targets were hybridized to Mouse Exon 1.0 ST arrays (Affymetrix), washed, stained, and
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scanned using standard protocols from the Siteman Cancer Center, Molecular and
Genomic Analysis Core Facility (http://pathology.wustl.edu/research/core
s/lcg/index.php).
Affymetrix CEL files were imported into Partek Genomics Suite™ 6.6 (Partek Inc., St.
Louis, MO). Probe-level data were pre-processed, including background correction,
normalization, and summarization, using robust multi-array average (RMA) analysis.
RMA adjusts for background noise on each array using only the PM probe intensities;
and subsequently normalizes data across all arrays using quantile normalization (49,50)
followed by median polish summarization to generate a single measure of expression
(50). Data was filtered to include only core probesets having raw expression signal
greater than 100 in all samples in order to limit the analysis within well-annotated exons.
The Analysis of Variance (ANOVA) and multi-test correction for p-values in Partek
Genomic Suite were used to identify differentially expressed genes. Sample genotypes
(WT; PR+/-; PR+/-, Dnmt3a-/-; and Dnmt3a-/-) were chosen as the candidate variables in
the ANOVA model to obtain genotype-specific expression changes. ANOVA p-values
were corrected using the Bonferroni method. The list of genes with significant variation
in expression level was generated by using a fold change of 2 and a 0.05 FDR criterion
as a significant cutoff.
Exon array data for all samples used in this study have been deposited on GEO
(http://www.ncbi.nlm.nih.gov/geo/: accession number GSE68844).
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HpaII qPCR Assay
DNA was isolated from MethoCult-plated cells after 1 week in MethoCult M3534 media,
and genomic DNA was isolated using QiAmp mini kit (Qiagen). 500 ng of genomic DNA
was digested with 0.5 uL (5 units) of HpaII enzyme (New England Biolabs) or mock
(water) for 90 minutes at 37o C, then heat inactivated at 80o C for 20 minutes. 1.5
microliters of each 30 microliter digest (25 ng gDNA) was amplified using KAPA SYBR
FAST qPCR Kit (KapaBiosystems) and PCR primers (IDT). Four amplified regions
were selected based on our methylation capture sequencing showing hypomethylation
in Dnmt3a-/- vs. wild-type cells, and ~200BP amplicons were designed containing HpaII
recognition sites (CCGG) using Primer3 software. Each sample was assayed in
triplicate. The percentage methylation was calculated at 2-delta Ct where delta Ct is
Ct(HpaII digested)-Ct(undigested).

Western Blotting
For blotting of whole embryos, E18 embryos were snap frozen in liquid nitrogen and
homogenized with mortar and pestle before lysis in RIPA buffer (50mM Tris pH 8.0, 150
mM NaCl, 0.1% SDS, 0.5% sodium deoxycholate, 1% NP-40) supplemented with
protease inhibitor cocktail (Sigma Aldrich). For blotting of retrovirus-transduced bone
marrow cells, 250,000 cells were rinsed with PBS and resuspended in urea lysis buffer
(7M urea, 2M thiourea, 30mM Tris pH 8.5) supplemented with protease inhibitor cocktail
and snap-frozen in liquid nitrogen. Lysates were boiled in 6X SDS loading dye (0.01M
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Tris HCl pH 6.8, 8% glycerol, 0.1 mg/ml bromophenol blue, 2% SDS, 1% Betamercaptoethanol) for 5 minutes at 95 degrees. Lysates were separated on a 10% SDSPAGE gel and transferred onto Hybond C Extra nitrocellulose membrane (Amersham).
The membrane was probed with an anti-Dnmt3A antibody (1:2000; Cell Signaling,
#2160), anti-Dnmt3B antibody (1:2000, Santa Cruz, sc-10236) or anti-αActin (1:5000;
Millipore). Immune complexes were revealed by peroxidase-conjugated anti-mouse IgG
(1:10,000; GE) or conjugated anti- rabbit IgG (1:2,500; GE) and visualized by
chemiluminescence (GE).

Cell Staining and Flow Cytometry
After ACK lysis of red blood cells, peripheral blood, bone marrow,or spleen cells were
treated with anti-mouse CD16/32 (clone 93, eBioscience) and stained with the indicated
combinations of the following antibodies (all antibodies are from eBioscience unless
indicated, see Supplemental Table 6): CD34 FITC (RAM34), CD11b PE or APC-e780
(M1/70), c-kit PerCP-Cy5.5 or APC-e780 (2B8), CD115 APC or PE (AFS98), Gr-1
Pacific-blue (Invitrogen, RM3028), Gr-1 biotin (RB6-8C5), B220 PE, APC, or biotin
(RA3-6B2), CD3 e450 or PE (145-2C11), CD71 PE( R17217), Ter-119 Pacific-blue
(TER-119), CD16/32 APC (93), Flk2 APC (A2F10). Analysis was performed using a
FACScan (Beckman Coulter) or I-Cyt Synergy II sorter (I-cyt Technologies), and data
analyzed using FlowJo (Tree Star), Excel (Microsoft), and Prism 5 (Graphpad).

Statistics
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All statistical comparisons were made using GraphPad Prism 5 software, except for
statistics on sequencing data, which were calculated using the R statistical
programming software as described above. Statistical tests employed and significance
cut-offs are detailed in each figure legend. When used, Student’s T-test was two-tailed
and a p value of less than 0.05 was considered significant. All data represent mean
plus/minus the standard error of the mean unless indicated.
Study Approval
All mouse procedures were done in accordance with institutional guidelines and
approved by the Animal Studies Committee at Washington University in accordance
with current NIH policies.
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2.8 Figure Legends

Figure 1
Dnmt3a is required for aberrant self-renewal ability conferred by PML-RARA on
hematopoietic progenitor cells. (A) Design of experiments in (B) through (E). Bone
marrow from 2-2.5 week old mice of the indicated genotypes was transduced with the
indicated retroviruses, plated in MethoCult media containing IL-3, IL-6, and SCF, and
then replated each week. (B) A YFP-expressing control vector does not induce
replating in WT or Dnmt3a-/- cells. (C)-(D) Dnmt3a is unnecessary for aberrant selfrenewal driven by retroviruses expressing MLL-AF9 (C) or RUNX1-RUNX1T1 (AMLETO).(D). E) Loss of Dnmt3a eliminates replating driven by a PML-RARA-containing
retrovirus. (F) Representative flow cytometry plots for the myeloid markers Gr-1 and
CD11b for week 1 vs. week 4 of replating. (G) Flow data for CD11b positivity week 4 of
replating, demonstrating loss of myeloid cells in Dnmt3a-/- marrow transduced with PMLRARA. N=3-6 for all experiments. *P<0.05, *** P<0.001 by two-tailed unpaired t-test.
Figure 2
Dnmt3a is required for aberrant self-renewal ability of PML-RARA (“PR”) expressing
mouse bone marrow cells ex vivo. (A) RT-PCR for PML-RARA expression in bone
marrow cells derived from Ctsg-PML-RARA mice (PR+/-), or Ctsg-PML-RARA mice that
are also deficient for Dnmt3a (PR+/-, Dnmt3a-/-). (B-C). Bone marrow from 2-2.5 week
old mice of the indicated genotypes was transplanted into lethally irradiated wild-type
recipients in a non-competitive transplant. (B) Quantification of cell numbers in the
mature myeloid compartment (Gr-1+, left panel) vs. the mature B cell compartment
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(B220+, right panel) at ten weeks post-transplant demonstrates ability of Dnmt3a-/donor stem cells to engraft and contribute normally to both myeloid and lymphoid
lineages (also see Supplementary Figure S3A). (C) Quantification of the indicated
progenitor and stem cell compartments shows no significant differences for any
genotype at ten weeks post-transplant. (D-F) Bone marrow from 2-2.5 week old mice of
the indicated genotypes was plated in MethoCult media containing IL-3, IL-6, and SCF,
and replated weekly. (D) Quantification of colony numbers demonstrates loss of colony
formation by PR+/-, Dnmt3a-/- cells. (E) Representative flow cytometry for the myeloid
markers Gr-1 and CD11b demonstrates loss of myeloid cells from PR+/-, Dnmt3a-/- mice
after two weeks of replating in MethoCult media. (F) Graph of CD11b positivity over
time. N=3-6 for all experiments.

*P<0.05, *** P<0.001 for PR+/- vs. all other genotypes

by two-way ANOVA.

Figure 3

Expression analysis of previously identified PML-RARA-dysregulated genes in GMP
cells derived from PR+/-, PR+/- Dnmt3a-/-, and Dnmt3a-/- mice. (A-B) Using Affymetrix
Mouse Exon 1.0ST arrays, we interrogated gene expression in GMP cells purified from
the bone marrow cells of mice transplanted with WT (N=4), PR+/- (N=2), PR+/-Dnmt3a/-

(N=4) and Dnmt3a-/-(N=3) marrow cells, and harvested 6-8 weeks later. (A) Mean fold

changes for 239 probesets that were previously found to be significantly dysregulated in
GMP cells derived from the bone marrow of 6-8 week old Ctsg-PMLRARA mice (labeled as PR+/-a) vs. WT GMP cells (N=4 for each, 30, Supp Table S3).
The mean fold changes (compared to WT GMP cells) for the 112 probesets that were
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upregulated in the PR+/-a are shown in the left panel, and the mean fold changes for the
127 probesets that were downregulated are on the right. Fold changes for the PR+/b,

PR+/- Dnmt3a-/-, and Dnmt3a-/- probesets were calculated by comparing to the WT

data from the current set of experimental data. (B). Heat map of Z-scored data using the
same 239 PR+/- dysregulated probesets defined in Wartman et al., and displaying the
average values obtained from the arrays generated from GMP purified cells with the
designated genotype used in this study. The list of genes with significant variation in
expression level was generated by using a fold change of 2 and a FDR criterion of less
than or equal to .05.

Figure 4
DNA methyltransferase activity of DNMT3A is required for aberrant self-renewal by
PML-RARA ex vivo. (A) Schematic of human DNMT3A cDNAs used in panels B
through E. Mutations in the methyltransferase domain (MTase) from AML patients
induce loss of catalytic function (R882H, red arrow) or lack the methyltransferase
domain altogether (Q615*, black arrow) (B) Western blot from PR+/- or PR+/-, Dnmt3a-/bone marrow cells transduced with retroviruses containing human DNMT3A cDNAs and
IRES-YFP, and then sorted for YFP+ cells. Cells were harvested after one week in
MethoCult medium. The positions of full length and truncated DNMT3A are indicated on
the right. (C) Bone marrow from 2-3 week old mice was transduced with the indicated
viruses, and GFP+ cells were sorted and serially replated in MethoCult medium. Week
4 colony numbers demonstrate that only wild-type DNMT3A with intact DNA
methyltransferase activity is able to restore colony formation to PR+/-, Dnmt3a-/- myeloid
cells.

(D) Flow cytometry of week 4 Methocult cells demonstrates persistence of
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CD11b expression in PR+/-, Dnmt3a-/- cells, conferred only by wild-type DNMT3A. (E)
Graph of CD11b expression percentages at four weeks of serial replating in MethoCult
medium. (F) Assay of methylation at a specific HpaII site in the Runx1 locus that is
dependent on Dnmt3a for methylation in wild-type bone marrow cells (Site 1 in
Supplemental Figure S1E). Re-expression of WT, full length DNMT3A by retroviral
transduction restores a normal level of methylation to these sites after seven days in
MethoCult media. Retroviruses containing mutant DNMT3A (R882H or Q615*) did not
restore methylation at this site. N=3-4 for all experiments. N.S. Not statistically
significant by two-way ANOVA, *P<0.05, **P<0.005, ***P<0.001.
Figure 5
Dnmt3b is not required for the aberrant self-renewal ability conferred by PML-RARA in
mouse bone marrow progenitor cells. (A) Design of experiments in (B) through (D).
Bone marrow from 2-2.5 week old mice of the indicated genotypes was plated in
MethoCult media containing IL-3, IL-6, and SCF and replated each week. B)
Quantification of colony numbers demonstrates no difference in colony formation in
PR+/-, Dnmt3b fl/fl cells with or without Vav-Cre. (C) Representative flow cytometry for
the myeloid markers Gr-1 and CD11b after week 6 MethoCult replating demonstrates
that self-renewal of myeloid cells from PR+/- mice is not dependent on Dnmt3b. (D)
Graph of CD11b positivity over time. (E) Design of experiment in (F). Marrow from 22.5 week old mice of the indicated genotypes was retrovirally transduced with MSCV
vectors containing WT DNMT3B-IRES-YFP or YFP only, and then sorted for YFP
positive cells and plated in MethoCult media as in (A). (F) Quantification of colony
numbers at week 4 illustrates that overexpression of DNMT3B is not able to rescue
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aberrant self-renewal in PR+/-, Dnmt3a-/- bone marrow cells. N=3-6 for all experiments.
N.S. Not statistically significant by two-tailed unpaired t-test, *P<0.05.
Figure 6
Dnmt3a is dispensable for leukemia induced by MLL-AF9 overexpression. (A) Design
of experiments in B through E. Bone marrow from 2-3 week old mice of the indicated
genotypes was harvested and transduced with an MLL-AF9 expressing retrovirus
before transplantation into lethally irradiated wild-type mice. (B) White blood cell counts
at 28 days post-transplant demonstrate an equal degree of leukocytosis in recipients of
MLL-AF9-transduced WT and Dnmt3a-/- bone marrow. (C) Spleen weights of moribund
animals were not significantly different regardless of Dnmt3a status. (D) MLL-AF9 was
able to initiate lethal leukemia with 100 percent penetrance and equal latency using
bone marrow cells with or without Dnmt3a (n = 11 for WT + MLL-AF9, n=9 for Dnmt3a-/+ MLL-AF9). N.S. Not significant by two-tailed unpaired t-test.
Figure 7
Dnmt3a is required for the competitive repopulation advantage conferred by PMLRARA, and its ability to induce APL in vivo. (A) Design of competitive transplant
experiments in (B)-(E), where marrow from 2-2.5 week old mice of the indicated
genotypes was mixed with wild-type competitor marrow and transplanted into lethally
irradiated recipients (week zero) for monitoring of relative contribution to peripheral
blood cells, bone marrow and spleen (n=4-21 per genotype). (B) Flow cytometry at the
indicated weeks post-transplant demonstrates that the competitive advantage for PR+/bone marrow in contributing to peripheral blood cells is completely abrogated in PR+/-,
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Dnmt3a-/- bone marrow, and that Dnmt3a-/- and PR+/-, Dnmt3a-/- bone marrow cells have
a competitive disadvantage versus wild-type marrow cells in this assay. (C)
Examination of chimerism in bone marrow and spleen at six months after
transplantation indicates a decreased contribution of PR+/-, Dnmt3a-/- marrow compared
to PR+/- marrow in both compartments. (D) Characterization of the stem/progenitor
compartments in chimeric mice 10 weeks after competitive transplantation. The
composition of all compartments is the same for both genotypes, except that PR+/-,
Dnmt3a-/- donors displayed a significantly increased contribution to the long-term
hematopoietic stem cell compartment. (E) Quantification of myeloid progenitor
compartments demonstrates no significant differentiation biases in either genotype. (F)
Long-term tumor watch of WT animals transplanted with PR+/- or PR+/-, Dnmt3a-/- bone
marrow demonstrated that 6/16 recipients of PR+/- and 0/13 recipients of PR+/-, Dnmt3a/- bone

marrow had succumbed to APL at one year post-transplant (P = 0.0336 by

Mantel-Cox Test). N.S. No differences between any two genotypes were statistically
significant by two-way ANOVA, **P<0.005, ***P<0.001 by two-way ANOVA.
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3.1 Abstract
Recent whole genome sequencing efforts by our group and others have identified recurrent
mutations in the DNA methyltransferase DNMT3A in various hematologic malignancies,
including acute myeloid leukemia (AML), MPN, MDS, CMML, and T-ALL. The most common
point mutation in AML, R882H, is nearly always heterozygous in AML, and has been
demonstrated to reduce enzyme activity by ~80%; the mutant protein also exerts a potent
dominant negative effect on the methylation activity of the wild-type protein. However, other
heterozygous mutations produce frameshifts, premature stop codons, or deletions of the entire
coding sequence of the gene, strongly suggesting that these mutations lead to simple
haploinsufficiency for DNMT3A. To test the hypothesis that Dnmt3a haploinsuffiency may
initiate AML, we performed a long-term tumor watch comparing wild-type mice (Dnmt3a+/+) to
mice carrying one wild-type Dnmt3a allele and one targeted allele that contains a neomycinresistance cassette inserted into the sequence coding for the catalytic domain of the protein,
producing a true null allele (Dnmt3a+/- mice). At 6 weeks of age, Dnmt3a+/- mice have normal
hematopoiesis, with no detectable differences from wild-type littermates in myeloid, lymphoid,
erythroid, or stem/progenitor populations in the bone marrow or spleen. However, after 1.5
years of age, 15/43 Dnmt3a+/- mice (35%) became moribund and were euthanized for
pathologic evaluation. Affected mice generally exhibited massive splenomegaly with myeloid
infiltration of the spleen, liver, and other extramedullary organs. At the conclusion of the tumor
watch at two years, all remaining mice were euthanized, and similar pathologic findings were
observed in an additional 9 Dnmt3a+/- mice, for an overall disease penetrance of 24/43 (56%).
In contrast, 0/20 WT littermate control animals developed myeloid malignancies over the same
time period. Flow cytometric evaluation of splenic tumors demonstrated positivity for the
myeloid markers Gr-1 and CD11b, and the presence of a subpopulation of Gr-1 and CD34
double positive cells. Based on flow cytometric and morphologic findings, we classified 16
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splenic tumors according to the Bethesda criteria: 11/16 had myeloid proliferative disease/MPD,
2/16 had myeloid leukemia with maturation, 2/16 had MPD-like myeloid leukemia, and 1 case
had myeloid sarcoma. Six tumors out of 18 tested were able to successfully engraft and lead to
lethal disease in sublethally irradiated wild-type recipients, providing further evidence that these
tumors represent transplantable, cell-autonomous myeloid malignancies. Analysis of exome
sequencing data from 5 primary tumor samples is ongoing. One MPD-like myeloid leukemia
was engrafted into four separate wild-type recipients, and all 5 tumors were sequenced.
Collectively, this set of samples was found to contain mutations in the Ras/MAPK pathway,
including the canonical gain-of-function mutation Kras G12C, a Ptpn11 E76K mutation, and a
missense mutation in the tumor suppressor Neurofibromatosis 1 (Nf1). A second, independent
primary tumor was also found to contain an activating Kras G13D mutation. Importantly, 9/51
AML samples with DNMT3A mutations in the TCGA AML cohort also contained activating
NRAS or KRAS mutations. Examination of the Dnmt3a locus in all 5 sequenced samples
revealed no evidence for mutations in or deletions of the residual wild-type Dnmt3a allele.
These data strongly suggest that Ras/MAPK pathway mutations can cooperate with Dnmt3a
haploinsufficiency to induce AML in C57Bl/6 mice and in humans.
3.2 Introduction
Recent whole genome sequencing efforts by our group have identified mutations in the
DNA Methyltransferase 3A (DNMT3A) gene in approximately 37% of AML patients with a
normal karyotype (22% of all cases)1. These mutations are almost always heterozygous, and
have been demonstrated by our group and others to be associated with high blast counts,
advanced age, and poor prognosis1–3. In addition, these mutations have been demonstrated to
be stable at relapse3, suggesting that they are probably in the founding clone for most patients.
DNMT3A mutations are enriched for changes at a single amino acid in the catalytic domain,
R882 (37 out of 62 DNMT3A-mutated patients in our study)1, but other patients had nonsense,

89

splice-site, and frame-shift mutations, and in one case, deletion of a 1.5 MB region including
DNMT3A1. Studies from our group and others confirmed that these heterozygous R882
mutations lead to a hypomorphic effect on the methyltransferase activity of the enzyme, and
also a dominant negative affect on the WT DNMT3A present in the same AML cells4,5.
DMNT3A with the R882H mutation forms stable heterodimers with WT DNMT3A, disrupting the
ability of the wild-type DNMT3A protein to form active homotetramers, and leading to a
canonical hypomethylation signature in DNMT3A R882H AML patients4.
In contrast to the dominant negative effect of R882H mutations, other DNMT3A
mutations are predicted to have translational effects that would disrupt the coding sequence by
introducing premature stop codons, frameshifts, or whole gene deletions1. These mutants
would not be predicted a priori to have dominant negative activity, suggesting that they create
simple haploinsufficiency for DNMT3A; this raises the possibility that simple haploinsufficiency
for DNMT3A may also be an initiating event for AML. Remarkably, AML samples with non-R882
mutations also have poor outcomes, but no discrete DNA methylation signature4.
Dnmt3a conditional null mice exhibit an aberrant expansion and loss of differentiation
potential in the long-term hematopoietic stem cell compartment when serially transplanted6, but
hematopoietic abnormalities in Dnmt3a+/- mice have not been reported. No phenotypic
abnormalities have been reported in Dnmt3a+/- mice, except for an increased variation in body
size that may reflect instability in quantitative traits induced by DNA hypomethylation7. Notably,
Dnmt3a+/- mice have not been monitored in a long-term tumor watch. Thus the effects of loss
of one copy of DNMT3A on normal hematopoiesis and leukemogenesis have not yet been
experimentally tested.
In the present study, we fully characterize hematopoiesis in Dnmt3a+/- mice, and
demonstrate that despite minimal effects on hematopoiesis in young mice, older mice
succumbed to a variety of myeloid malignancies (including myeloproliferative disease, myeloid
sarcoma, and acute myeloid leukemia) after a very long latent period,. Transplantation of these

90

tumors into sublethally irradiated wild-type recipient mice allowed for studies of the clonality of
the tumors using exome sequencing on the primary and secondary tumors. These data
revealed mutations in the RAS-MAPK pathway in 2/5 samples; these mutations became
enriched in secondary tumors. Together, these studies suggest that loss of one copy of Dnmt3a
can facilitate leukemogenesis in both mice and AML patients.

3.3 Results
Dnmt3a+/- mice exhibit normal hematopoiesis
To characterize the effect of loss of one copy of Dnmt3a on hematopoiesis, we used a
previously described Dnmt3a constitutive knockout mouse with a neomycin resistance cassette
inserted into the exons coding for the catalytic domain of Dnmt3a8. We have verified that this
allele produces no detectable Dnmt3a protein, including any truncated forms, by western
blotting of whole embryos with an N-terminal Dnmt3a antibody. We intercrossed WT C57Bl/6
mice with Dnmt3a+/- mice to generate Dnmt3a+/- mice and Dnmt3a+/+ littermates. Dnmt3a+/mice were born at Mendelian ratios and did not exhibit the severe runting phenotype that leads
to premature death in Dnmt3a-/- mice (data not shown). 6 week-old Dnmt3a+/- and Dnmt3a+/+
mice were euthanized and bone marrow was harvested for study of mature lineage
compartments (myeloid, B and T cells, Figure 1A) as well as for myeloid precursors (GMP,
CMP, MEP) and long-term hematopoietic cells (KLS-SLAM cells, Figure 1B). No differences
between wild-type and Dnmt3a+/- bone marrow cells were present in any of these
compartments. Microarray analysis of gene expression in an enriched progenitor population of
these mice (KLS cells) uncovered no signature for the Dnmt3a+/- cells, and unsupervised
clustering using the top 5000 genes with the highest variance did not cluster the samples by
genotype (Figure 1C).
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Loss of one copy of Dnmt3a did not lead to an aberrant self-renewal phenotype when
whole bone marrow from these mice was serially replated in methocult media (Figure 1D).
When whole bone marrow cells from 6-week-old Dnmt3a+/- animals were competed against
wild-type bone marrow in a competitive transplant experiment, there was no advantage for
Dnmt3a+/- bone marrow over time (Figure 1E); no apparent lineage bias was detected in the
peripheral blood cells of Dnmt3a+/- donor cells (Figure 1F). A large cohort of Dnmt3a+/- (n=43)
and WT mice (n=20) was set up and was bled at regular intervals for studies of peripheral blood
counts by automated CBC, and no differences were exhibited between either genotype at any
time point up to one year (data not shown). Collectively, these studies demonstrate that loss of
one copy of Dnmt3a does not grossly perturb hematopoiesis or induce a specific gene
expression signature in the progenitor cells of young Dnmt3a+/- mice.
Dnmt3a+/- mice develop myeloid malignancies with long latency
To test whether loss of one copy of Dnmt3a leads to hematopoietic changes in older
mice, we monitored our cohort of Dnmt3a+/- and wild-type mice in a tumor watch for two years.
Beginning at 1.5 years, some Dnmt3a+/- mice (15/43, 35%) became moribund, exhibiting
lethargy, abdominal bloating, ruffled fur, and pale extremities (Figure 2A). Affected mice were
euthanized and were found to have varying degrees of hepatosplenomegaly, with myeloid
infiltrates in the spleen, liver, and other organs, including the mediastinal and cervical lymph
nodes. At the conclusion of the tumor watch at two years, all remaining mice were euthanized
for pathologic examination, and an additional 9 Dnmt3a+/- mice were found to display similar
pathologic findings, for an overall disease penetrance of 24/43 (56%). “Affected mice” had
spleen sizes greater than 5 standard deviations above the mean of spleen size of wild-type mice
at 2 years (Figure 2B). In addition to splenomegaly, many Dnmt3a+/- mice displayed anemia
and thrombocytopenia, but not significant leukocytosis. Flow cytometry of the spleen cells of
affected animals revealed positivity for the myeloid markers Gr-1 and/or CD11b (Table1). In
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addition, many spleens contained sizable populations of cells that were double positive for both
the late myeloid marker Gr-1, and the progenitor marker CD34, a hallmark of leukemic myeloid
cells. No cases of myeloid disease were observed in 20 wild-type mice during the duration of
the tumor watch.
On the basis of flow cytometry and histopathologic findings, 11 of the 16 splenic tumors
were classified (Bethesda criteria9) as myeloproliferative disease/MPD, two had myeloid
leukemia with maturation, two had MPD-like myeloid leukemia, and one had a myeloid sarcoma
(Figure 2C-D and Table 1).
Transplantable Tumors from Dnmt3a+/- mice exhibit mutations in the Ras-MAPK pathway
Six tumors out of 16 that were tested were able to be secondarily transplanted and
induce acute disease in sub-lethally irradiated wild-type secondary recipients, with median
disease latencies ranging from 26-90 days for each tumor (Figure 3A). Flow cytometry and
gross pathologic examination demonstrated that tumors derived from the secondary animals
were myeloid malignancies that recapitulated the cell surface phenotypes of the primary tumors
(Figure 3B).
Whole exome sequencing was performed to analyze the mutational spectrum in the
primary and secondary tumors from these mice. Tumors were compared against sorted B220+
B cells from the primary animal’s spleen, as a normal control population. Sequencing of DNA
derived from unsorted spleen cells yielded low variant allele frequencies (VAF) for most putative
mutations in the primary tumors, probably because all tumors were heavily contaminated with
non-malignant lymphocytes (data not shown). All tumors were therefore resorted for Gr-1
CD34+ double-positive cells to enrich for the myeloid tumor population. In several of these
tumors, potential cooperating mutations were identified. In particular, analysis of one primary
MPD-like myeloid leukemia (and secondary tumors derived from it) revealed somatic mutations
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in the Ras-MAPK pathway, including a putative loss-of-function mutation in the tumor
suppressor Nf1 (R1444I), and canonical activating mutations in SHP2 (E76K) and in Nras
(G12C) (Figure 3C). A second independent primary tumor contained a canonical gain-offunction mutation in Nras (G13D).
These mutations were present at a higher VAF in the secondary tumors than the primary
tumor, suggesting that they were part of a subclone in the primary tumor that was selected for
when engrafted into secondary recipients. Interestingly, 9 of 51 AML patient samples with
DNMT3A mutations from the TCGA study also contained Nras or Kras mutations10. This
suggests that loss of Dnmt3a function and mutations in the Ras-MAPK pathway can cooperate
in both humans and Dnmt3a+/- mice.
Tumors from Dnmt3a+/- mice retain the residual wild-type Dnmt3a allele
We examined the sequence of the residual wild-type Dnmt3a allele in all tumors to see
whether it was still wild type, or whether loss of heterozygosity (LOH) affected the residual
allele. No point mutations or indels in the residual Dnmt3a allele were detected by our mutationcalling algorithm, and this result was confirmed by manual review of the Dnmt3a coding
sequence. A specialized algorithm for detecting copy number changes, CopyCat2, did not
detect additional copy number changes at the Dnmt3a locus in any of the four sequenced
tumors. This result is currently being corroborated by comparing the Dnmt3a locus to that in
wild-type controls, but our preliminary analyses indicate that the wild-type Dnmt3a allele is
maintained in these tumors.
3.4 Discussion
In this study, we investigated hematopoiesis and leukemia development in Dnmt3a+/mice. We found that although young Dnmt3a+/- mice exhibited no hematopoietic abnormalities
or aberrant self-renewal phenotypes, 56% of Dnmt3a+/- mice developed myeloid diseases after
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a very long latent period. Several of these malignancies were transplantable to sub-lethally
irradiated wild-type recipients. Exome sequencing of primary tumors, and corresponding
engrafted secondary tumors, revealed that 2/4 tumors tested had mutations in the Ras-MAPK
pathway, which mimics NRAS and KRAS mutations in human AML patients with DNMT3A
mutations. Finally, our sequencing studies revealed that the residual wild-type Dnmt3a allele
was intact and not mutated in these tumors; these malignancies were therefore haploinsufficient
for Dnmt3a, not deficient for this protein.
The motivation for this study was provided by the observation that many mutations at the
DNMT3A locus in AML cases apparently cause haploinsufficiency (i.e. frameshifts and whole
gene deletions)1. We discovered that Dnmt3a+/- mice developed a variety of myeloid
malignancies with very long latencies. These malignancies were often aggressive, with most
cases exhibiting massive splenomegaly and leukemic infiltrates into various extramedullary
tissues. While DNMT3A mutations are found in both myeloid and lymphoid malignancies, they
are much more prevalent in myeloid malignancies; likewise, we did not detect any lymphoid
malignancies in the Dnmt3a+/- mice. This is particularly striking, since C57 Bl/6 mice have a
greater tendency to spontaneously develop lymphoid vs. myeloid malignancies11–13, and it
suggests that haploinsufficiency for Dnmt3a specifically facilitates myeloid leukemogenesis.
The long latency of leukemia development in Dnmt3a+/- mice suggests the need for
cooperating mutations for the development of overt leukemia. By performing whole exome
sequencing of primary tumors and their corresponding engrafted tumors from wild-type
recipients, we were able to identify cooperating hits in the Ras-MAPK pathway in two separate
tumors. Several of these are well characterized oncogenic mutations that lead to activation of
the RAS-MAPK pathway, and result in increased proliferative activity in various cell types14.
Both NRAS and KRAS mutations frequently occur in human AML patients with mutant
DNMT3A10, and studies in mice have demonstrated the ability of RAS and NF1 mutations to
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cooperate with other AML-initiating mutations, such as PML-RARA15, AML-ETO16,17 and MLL
fusions17,18.
DNMT3A R882H mutations in AML are almost always heterozygous, because this
mutation creates a protein that is a potent dominant negative inhibitor of WT DNMT3A4.
Although rare AML patients appear to have biallellic mutations in DNMT3A, many others appear
to have heterozygous mutations that cause simple haploinsufficiency1. The development of
leukemias in our Dnmt3a+/- mice raised the question of whether the residual allele was
mutationally inactivated in the manner of a classical “two hit” tumor suppressor. However, we
found no evidence for this phenomenon, suggesting that myeloid malignancies that arise in
these mice result from simple haploinsufficiency of Dnmt3a.
Since their initial discovery in AML patients, DNMT3A mutations have been implicated in
a variety of hematologic malignancies, including MPN, MDS, CMML, and T-ALL19. In this study,
we discovered numerous myeloid malignancies in our Dnmt3a+/- mice with retention of the wildtype Dnmt3a allele. Mutational hits in the Ras-MAPK pathway in multiple tumors mirrored
similar findings in DNMT3A-mutated AML patients, and are suggestive of the ability of DNMT3A
mutations to cooperate with mutations in the Ras-MAPK pathway to drive leukemogenesis.
These studies shed light on the clinical observation that many DNMT3A mutations are predicted
to lead to inactivation of one copy of the gene, and suggest that simple haploinsufficiency for
DNMT3A facilitates the development of myeloid leukemia in mice and in humans.
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3.5 Methods
Mice
The Dnmt3a-/- mice have been previously described. Dnmt3a+/- mice were obtained from the
Mutant Mouse Regional Resource Centers repository (MMRRC Strain Name B5.129S4Dnmt3atm2Enl/Mmnc). Whenever possible, littermate controls were used for all experiments. All
mouse procedures were done in accordance with institutional guidelines and approved by the
Animal Studies Committee at Washington University in accordance with current NIH policy.
Bone Marrow Harvest and Transplantation
Bone marrow was harvested from femurs, tibias, pelvi, and humeri of 6-week-old mice. After
lysis of red blood cells (ACK buffer: 0.15 M NH4Cl, 10 mM KHCO3, 0.1 mM Na2EDTA), cells
were washed with FACS buffer, filtered through through 50-μm cell strainers (Partec) and
resuspended in PBS at 1 million cells/100 uL for transplantation. For competitive transplant
experiments, bone marrow was mixed 50:50 with freshly harvested cells from 6-week-old Ly5.1
mice (The Jackson Laboratory, Bar Harbor, ME). Transplantation was performed by retroorbital injection of 1 × 106 total bone marrow cells into lethally irradiated Ly5.2 or Ly5.1x5.2
recipients that had received 2 split doses of 550 cGy total body irradiation spaced at 4 hours
(Mark 1 Cesium-137 irradiator, JL Shepherd) 24 hours prior to transplantation. For tumor
transplants, recipient Ly5.1 mice were sublethally irradiated (600 cGy) and retro-orbitally
injected with 1 million tumor cells.
Mouse Analysis and Tumor Watch
Peripheral blood counts were assessed at regular intervals as indicated by automated CBC
(Hemavet 950, Drew Scientific Group). For long-term tumor watch experiments, bone marrow
transplant recipients were monitored daily and animals displaying signs of illness (lethargy,
hunched posture, ruffled fur, dyspnea, or palor) were euthanized and spleen and bone marrow
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harvested for analysis. Diagnosis of leukemia was made by light microscopic examination of
spleen and/or peripheral blood cells according to the Bethesda criteria. Cytospin tissue slides
were stained with Wright-Giemsa stain (Sigma-Aldrich) and were imaged using a Nikon
MICROPHOT-SA microscope equipped with an oil-immersion 50×/0.90 or 100×/1.30 objective
lens (Nikon Corp.) The tumor watch was terminated after 1 year post-transplant, at which timepoint recipients of wild-type marrow begin to succumb to complications related to the irradiation
procedure.
Methylcellulose Colony Formation Assay
10,000 cells per plate were plated in triplicate in M3534 Methocult media containing Il-3, Il-6,
and SCF (Stem Cell Technologies) and incubated at 37 degrees for 1 week. Each week,
clusters of cells meeting the morphologic criteria for CFU-GEMM, CFU-GM, CFU-G, or CFU-M
(http://www.stemcell.com/~/media/Technical%20Resources/8/3/E/9/0/28405_methocult%20M.p
df?la=en) were counted as myeloid colonies and cells were lifted using warm DMEM media +
2% FBS, spun down, and replated as before. An aliquot of cells was taken for analysis of
myeloid markers by flow cytometry.
Illumina library construction and exome sequencing
Genomic DNA from all tumor samples and/or matched normal samples were fragmented using
a Covaris LE220 DNA Sonicator (Covaris, Woburn, MA) within a size range between 100-400bp
using the following settings: volume = 50µL, temperature = 4°C, duty cycle = 20, intensity = 5,
cycle burst = 500, time = 120 seconds. The fragmented samples were transferred from the
Covaris plate and dispensed into a 96 well BioRad Cycle plate by the CyBio-SELMA instrument.
Small insert dual indexed Illumina paired end libraries were constructed with the KAPA HTP
sample prep kit according to the manufacturer's recommendations (KAPA Biosystems, Woburn,
MA) on the SciClone instrument according to the manufacturer's recommendations (Perkin
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Elmer, Waltham, MA). Dual indexed adaptors were incorporated during ligation; the same 8bp
index sequence is embedded within both arms of the library adaptor. Libraries were enriched
with a single PCR reaction for 8 cycles. The final size selection of the library was achieved by a
single AMPure XP paramagnetic beads (Agencourt, Beckman Coulter Genomics, Beverly, MA)
cleanup targeting a final library size of 300-500bp. The libraries undergo a qualitative (final size
distribution) and quantitative assay using the HT DNA Hi Sens Dual Protocol Assay with the HT
DNA 1K/12K chip on the LabChip GX instrument (Perkin Elmer, Waltham, MA).
Libraries were captured using the Nimblegen SeqCap EZ Library reagent. The final
concentration of each capture pool was verified through qPCR utilizing the KAPA Library
Quantification Kit - Illumina/LightCycler® 480 kit according to the manufacturer's protocol (Kapa
Biosystems, Woburn, MA) to produce cluster counts appropriate for the Illumina HiSeq2000
platform. Each capture pool was loaded on the HiSeq2000 version 3 flow cell according to the
manufacturer's recommendations (Illumina, San Diego, CA). 2 X 101bp read pairs were
generated for each sample, yielding approximately 6-7Gb of data per sample.
Variant detection pipeline
Sequence data was aligned to mouse reference sequence mm9 (with the OSK vector sequence
added) using bwa version 0.5.9[14] (params: -t 4 -q 5::). Bam files were deduplicated using
picard version 1.46.
Single Nucleotide Variants (SNVs) were detected using the union of three callers: 1) samtools
version r963[15] (params: -A -B) intersected with Somatic Sniper version 1.0.2[16] (params: -F
vcf -q 1 -Q 15) and processed through false-positive filter v1 (params: --bam-readcount-version
0.4 --bam-readcount-min-base-quality 15 --min-mapping-quality 40 --min-somatic-score 40) 2)
VarScan version 2.2.6[17] filtered by varscan-high-confidence filter version v1 and processed
through false-positive filter v1 (params: --bam-readcount-version 0.4 --bam-readcount-min-
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base-quality 15 --min-mapping-quality 40 --min-somatic-score 40), and 3) Strelka version
0.4.6.2[18] (params: isSkipDepthFilters = 1).
Indels were detected using the union of 4 callers: 1) GATK somatic-indel version 5336[19]
filtered by false-indel version v1 (params: --bam-readcount-version 0.4 --bam-readcount-minbase-quality 15), 2) pindel version 0.5[20] filtered with pindel false-positive and vaf filters
(params: --variant-freq-cutoff=0.08), 3) VarScan version 2.2.6[17] [filtered by varscan-highconfidence-indel version v1 then false-indel version v1 (params: --bam-readcount-version 0.4 -bam-readcount-min-base-quality 15), and 3) Strelka version 0.4.6.2[18] (params:
isSkipDepthFilters = 1).
Variants were filtered to remove non-homozygous or heterozygous sites using an R script
(https://github.com/genome/gmscore/blob/f00200864a9d0b87e6b6257c5e6bcadab4e6f685/lib/perl/Genome/Model/Tools/Analysi
s/RemoveContaminatingVariants.R)
Cell Staining and Flow Cytometry
After ACK lysis of red blood cells, peripheral blood, bone marrow,or spleen cells were treated
with anti-mouse CD16/32 (clone 93, eBioscience) and stained with the indicated combinations
of the following antibodies (all antibodies are from eBioscience unless indicated): CD34 FITC
(RAM34), CD11b PE or APC-e780 (M1/70), c-kit PerCP-Cy5.5 or APC-e780 (2B8), CD115 APC
or PE (AFS98), Gr-1 Pacific-blue (Invitrogen, RM3028), Gr-1 biotin (RB6-8C5), B220 PE, APC,
or biotin (RA3-6B2), CD3 e450 or PE (145-2C11), CD71 PE( R17217), Ter-119 Pacific-blue
(TER-119), CD16/32 APC (93), Flk2 APC (A2F10). Analysis was performed using a FACScan
(Beckman Coulter) or I-Cyt Synergy II sorter (I-cyt Technologies), and data analyzed using
FlowJo (Tree Star), Excel (Microsoft), and Prism 5 (Graphpad).
Exon Array Gene Expression Analysis
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For expression array profiling, total cellular RNA was purified using TRIzol reagent (Invitrogen),
quantified using UV spectroscopy (Nanodrop Technologies), and qualitatively assessed using
an Experion Bioanalyzer. Amplified cDNA was prepared from 20 ng total RNA using the whole
transcript WT-Ovation RNA Amplification System and biotin-labeled using the Encore Biotin
Module, both from NuGen Technologies, according to the manufacturer's instructions. Labeled
targets were then hybridized to Mouse Exon 1.0 ST arrays (Affymetrix), washed, stained, and
scanned using standard protocols from the Siteman Cancer Center, Molecular and Genomic
Analysis Core Facility (http://pathology.wustl.edu/research/cores/lcg/index.php). Affymetrix
Expression Console software was used to process array images, export signal data, and
evaluate image and data quality relative to standard Affymetrix quality control metrics. Gene
expression analysis was carried out in R using packages available through Bioconductor
(www.bioconductor.org).
Statistics
All statistical comparisons were made using GraphPad Prism 5 software, except for statistics on
sequencing data, which were calculated using the R statistical programming software as
described above. Statistical tests employed and significance cut-offs are detailed in each figure
legend. All data represent mean plus/minus the standard error of the mean unless indicated.
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3.7 Figure Legends
Figure 1
Normal hematopoiesis in young Dnmt3a+/- mice. (A) Quantification of myeloid cells (Gr-1+),
B220+ B cells, and CD3+ T cells in bone marrow of 6-week-old wild-type and Dnmt3a+/- mice.
(B) Quantification of myeloid progenitor compartments (GMP, CMP, MEP) and KLS-SLAM cells
(HSC) from young mice as in A). (C) Unsupervised hierarchical clustering of exon array data
from sorted enriched progenitor cells (KLS cells) from 6-week-old mice in which samples are
clustering using the 5000 probes with the highest standard deviation demonstrates the lack of a
distinct gene expression signature in Dnmt3a+/- cells v. wild-type. (D) Bone marrow from 6week-old mice was plated in methocult media containing IL-3, IL-6 and SCF, and replated every
7 days. Quantification of colony numbers demonstrates that Dnmt3a+/- cells have no aberrant
self-renewal phenotype ex vivo. (E-F) Bone marrow from 6-week-old wild-type or Dnmt3a+/mice was mixed 50:50 and transplanted into lethally irradiated wild-type mice. (E) Chimerism in
peripheral blood at 16 weeks demonstrates no competitive advantage for Dnmt3a+/- donor cells
versus wild-type. (F) Lineage bias for each donor genotype was quantified by measuring
dividing the number of cells positive for each marker by the total chimerism. No lineage biases
were detected for Dnmt3a+/- vs wild-type bone marrow cells. N.S. = not significant by two-way
ANOVA with Bonferroni post-test. N=3 for all experiments.
Figure 2
Dnmt3a+/- mice develop myeloid malignancies. (A) Dnmt3a+/- and wild-type mice were
monitored in long-term (2 year) tumor watch and mice which became moribund were euthanized
for pathologic analysis. (B) At 2 years all remaining mice were bled for CBCs, euthanized, and
all mice on tumor watch were grouped by spleen size into wild-type, unaffected Dnmt3a+/-, and
affected Dnmt3a+/- (see Results for details). Affected Dnmt3a+/- mice exhibited anemia and
thrombocytopenia but not significant leukocytosis. (C) Distribution of pathologic diagnoses
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according to Bethesda criteria for all mice that could be definitively classified. (D)
Representative histology of tissues from affected Dnmt3a+/- mice. *p<0.05, ***p<0.001 by twotailed t-test.
Figure 3
Transplantable tumors from Dnmt3a+/- mice exhibit mutations in the Ras-MAPK pathway. (A)
Kaplan-Meier curve illustrating disease latency for sublethally irradiated wild-type animals
engrafted with Dnmt3a+/- tumors. (B) Representative flow cytometry from primary and
secondary tumors demonstrating that secondary tumors recapitulate the immunophenotypes of
their corresponding primary tumors. (C) Schematic of Ras-MAPK pathway illustrating location
of mutations in Dnmt3a+/- tumors discovered by exome sequencing of sorted Gr-1+Cd34+ cells.
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Figure 3
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Table 1
Case Spleen
Wgt (g)

Gr1+

CD11b+ Gr1+CD34+ Gr1+ckit+ B220+ CD3+

Pathologic Diagnosis

1

4

85.7

94.5

50.4

3.2

Myeloid proliferation (nonreactive); Myeloproliferative disease

2

0.82

84.1

99.1

36.2

1.6

3

2.7

50.3

69.8

17.9

4.3

5.7

16.6

Myeloid proliferation (nonreactive); Myeloproliferative disease

4

0.44

33.1

64.8

12.1

1.1

9.7

6.6

Myeloid proliferation (nonreactive); Myeloproliferation (genetic)

5

0.92

43.2

75.4

20.1

1.8

1.7

6.8

Myeloid leukemia; MPD-like myeloid leukemia

6

0.5

4.1

24.9

1.3

0.2

12.1

2.9

Myeloid leukemia; MPD-like myeloid leukemia

7

1.77

1.3

2.3

0.5

0.0

0.1

4.3

Myeloid proliferation (nonreactive); Myeloproliferation (genetic)

8

2.02

1.9

5.8

1.0

0.2

0.1

6.6

Myeloid proliferation (nonreactive); Myeloproliferation (genetic)

9

1.55

3.4

6.0

1.0

0.2

0.3

3.0

Myeloid leukemia with maturation

10

N/A

11

1.56

54.9

71.7
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0.5

7.5

24.2

Myeloid proliferation (nonreactive); Myeloproliferation (genetic)

12

5.22

52.7

72.6

41.3

1.6

0.9

34.6

Myeloid proliferation (nonreactive); Myeloproliferation (genetic)

13

4.77

56.3

81.1

41.7

1.9

4.9

16.1

Myeloid proliferation (nonreactive); Myeloproliferation (genetic)
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1.27

71.8

92.1

32.6

0.4

3.5

9.3

Myeloid proliferation (nonreactive); Myeloproliferation (genetic)

15

0.56

48.6

69.7

29.3

0.3

16.3

10.3

Myeloid proliferation (nonreactive); Myeloproliferation (genetic)

16

4.17

60.1

84.5

37.7

1.3

2.3

21.6

Myeloid proliferation (nonreactive); Myeloproliferation (genetic)

1.0

23.6

Myeloid leukemia with maturation

Myeloid Sarcoma

109

Chapter 4

Summary and Future Directions
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4.1 Summary
In this thesis, we used mouse models of acute myeloid leukemia in order to explain two
observed patterns of mutations that have emerged from recent whole genome sequencing of
acute myeloid leukemia patients. In Chapter 2, we applied well-characterized retroviral and
transgenic mouse models to investigate the mechanistic basis for the observation that DNMT3A
mutations are exclusive of the common fusion proteins PML-RARA, RUNX1-RUNX1T1, and the
MLL fusions. We discovered that of these fusion genes, only PML-RARA is dependent on
Dnmt3a for its ability to drive aberrant self-renewal ex vivo, and provide a competitive
advantage and leukemia in vivo. The ability to drive aberrant self-renewal is specifically
dependent on the methyltransferase activity of Dnmt3a, since neither DNMT3B nor catalytically
deficient DNMT3A mutants are able to restore aberrant self-renewal to Ctsg-PML-RARA bone
marrow cells lacking Dnmt3a. Using a methylation-sensitive restriction enzyme, we
demonstrated that restoration of self-renewal ability by expression of retroviral DNMT3A
coincides with restoration of DNA methylation at several informative loci. In Chapter 3, we
studied Dnmt3a+/- mice to model a subset of DNMT3A mutations observed in AML patients (i.e.
heterozygous mutations predicted to create haploinsufficiency for DNMT3A). We discovered
that although young Dnmt3a+/- mice exhibit no detectable hematopoietic abnormalities
(including a lack of a competitive transplant advantage, and no aberrant self-renewal phenotype
ex vivo), a long-term tumor watch demonstrated the development of myeloid malignancies in
approximately 60% of animals, with a very long latency (1.5 years or longer). Some of these
tumors were transplantable to sublethally irradiated wild-type recipients, and resulted in tumors
that were morphologically and immunophenotypically similar to the primary tumors from which
they were derived. Whole exome sequencing demonstrated mutations in the Ras-MAPK
pathway in several tumors, and also verified that the residual Dnmt3a wild-type allele was intact,
demonstrating that these phenotypes are due to Dnmt3a haploinsufficiency. In Chapter 4, we
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will examine unresolved questions raised by these results, and propose future experiments
designed to investigate the role of DNMT3A in APL and DNMT3A haploinsufficiency in AML.
4.2 Early and late epigenetic changes in Ctsg-PML-RARA mice
The observation that the DNA methylation signature of APL patients can distinguish
them from cases with the other chromosomal fusions--as well as all other AML cases--is striking
and has been observed by multiple groups1,2. This finding, and our observation of abrogation of
aberrant self-renewal and disruption of leukemogenesis in PR+/-, Dnmt3a-/- mice, strongly
suggest a role for DNA methylation in the pathogenesis of APL, but the nature of the precise
methylation changes and their relationship to PML-RARA activity remain unclear. Previous
studies of methylation signatures in APL have largely been limited to technologies such as
reduced representation bisulfite sequencing, which is capable of interrogating the methylation
status of a small fraction of genomic CpGs3–5. Further, all studies to date have also focused on
fully transformed APL cells. In addition, studies of methylation in APL patient cells have lacked
appropriate controls that are critical to determine “normal” methylation patterns.
The gold standard for interrogating genomic methylation is whole genome bisulfite
sequencing, which allows a non-biased measurement of CpG methylation across the genome6.
Presently we are initiating studies of whole genome bisulfite sequencing to examine methylation
patterns in 1) the non-leukemic promyelocytes of 6-week-old mCG-PML-RARA+/- mice, 2)
promyelocytes of wild-type littermates, and 3) APL samples from mCG-PML-RARA+/- mice.
The promyelocyte compartment was chosen because it is an enriched progenitor compartment
with high expression of the PML-RARA allele, and well-documented dysregulation of many
genes by PML-RARA7. Using this system, we will interrogate early methylation changes
induced by PML-RARA expression relative to a wild-type control, and we will compare these
changes to the methylation state of fully transformed tumors from the same mouse model. This
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experiment will elucidate early methylation events induced by PML-RARA at high resolution.
Additional interrogation of chromatin modifications and accessibility, using techniques such as
H3K27 and H3K4 ChIP-seq and ATAC-seq8, will allow for a comprehensive description of the
epigenetic changes accompanying PML-RARA expression in preleukemic and leukemic mice.
4.3 Elucidation of the Mechanisms by which PML-RARA and Dnmt3a Affect Gene
Expression
The classical model of PML-RARA function is that fusion to PML disrupts the ability of
RARA to release from DNA, thus leading to a repression of gene expression that is
unresponsive to endogenous retinoic acid ligand, possibly by recruitment of a co-repressive
complex that includes Dnmt3a9. However, early gene expression changes in the myeloid
progenitor compartment of mCG-PML-RARA+/- mice include both down-regulated and upregulated genes7. Further, confirmation of a direct PML-RARA-DNMT3A protein-protein
interaction has not yet been reported by any lab. We are currently performing rigorous pulldown experiments to establish whether PML-RARA and DNMT3A are in fact capable of a direct
interaction, and also establishing whether this interaction exists between PML-RARA and
mouse Dnmt3a, since this is directly relevant to understanding the requirement for functional
Dnmt3a in our Ctsg-PML-RARA mouse.
Another outstanding question concerns the relationship between PML-RARA binding
and induction of DNA methylation. Although it is clear from our studies that PML-RARA needs
functional Dnmt3a to drive leukemogenesis, it is still unclear whether this reliance is the direct
result of PML-RARA recruitment of Dnmt3a to methylate and repress DNA target genes, as has
been proposed9,10. Efforts to relate PML-RARA binding and DNA methylation genome-wide
have relied on a correlative approach (using two antibodies against RARA and PML) and have
only been able to capture DNA methylation changes in a limited fashion (using RRBS at an
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early time point after induction of PML-RARA expression, in a transformed cell line)3. To
circumvent these limitations, we will express a tagged version of PML-RARA in mouse bone
marrow cells, and allow it to stably engraft in recipients before harvesting expressing cells for
PML-RARA ChIP-seq. This approach will allow us to interrogate PML-RARA binding in an
endogenous cellular context, and in combination with the above studies of DNA methylation and
chromatin conformation, will enable a genome-wide view of how PML-RARA binding relates to
local DNA methylation and chromatin conformation changes. Finally, the above data will be
combined with comprehensive RNA-sequencing to describe the relationships between PMLRARA binding, the induction of chromatin structure changes, and changes in gene expression.
4.4 Examination of DNA Methylation in Dnmt3a+/- Mice
A DNA methylation analysis has not yet been reported for Dnmt3a+/- mice. Future
research will seek to determine whether loss of one copy of Dnmt3a results in hypomethylation
at specific canonical loci, for example the Dnmt3a-dependent loci identified in our methylation
sequencing studies in Chapter 2. Given the lack of detectable hematopoietic abnormalities in
young Dnmt3a+/- mice, it is possible that a methylation deficit in these mice due to
haploinsufficiency for Dnmt3a is far more subtle than that in Dnmt3a-null mice, requiring multiple
divisions of hematopoietic stem cells throughout the lifespan of the mouse in order to
accumulate changes in CpG methylation. This, along with the need for cooperating mutations
such as those in the Ras-MAPK pathway, might explain the very long latency to leukemia in the
Dnmt3a+/- mice. One method to examine a possible progressive methylation deficit is to
serially examine methylation in Dnmt3a+/- bone marrow cells in mice of different ages, using
either the HpaII assay we employed in this thesis, or a more comprehensive genome-wide
approach. Additional experiments that might support the hypothesis of a progressive
methylation deficit would include examining the methylation state in cultured cells induced to
rapidly proliferate, e.g. by growth of a small starting number of bone marrow cells expanded on
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stromal cells in the presence of cytokines, or in mice treated with 5-FU to induce rapid stem cell
expansion. Methylation changes at individual loci observed in these studies will need to be
correlated with gene expression changes to determine their role in the development of disease.
4.5 Identification and Phenotyping of DNMT3A-Haploinsufficient Patients
Our group has made considerable progress in understanding the dominant negative
mechanism of DNMT3A R882H mutations, and correlating these with a canonical
hypomethylation phenotype in patients11, but other DNMT3A mutations remain poorly
understood. While it can be confidently predicted that some DNMT3A mutations, such as a
whole gene deletion, will result in protein production from only one allele12, this needs to be
empirically tested for other mutations. For many of the frame-shift mutations, it is likely that
premature termination leads to induction of nonsense-mediated decay, but it is also formally
possible that some of these mutations result in formation of a truncated protein with biochemical
activity. For DNMT3A nonsense and missense mutations, the effect of expression of the
mutated allele on the methylation activity of the wild-type allele remains to be determined. We
are currently in the process of creating expression constructs for a number of these DNMT3A
mutations to determine which lead to production of a DNMT3A protein. The mutant alleles that
result in expression of detectable protein will be further evaluated with biochemical studies to
quantify their degree of methylation activity and their effects on wild-type DNMT3A, using
methods previously published by our group11.
By biochemically characterizing these mutant DNMT3A alleles, we will be able to
determine which alleles lead to true haploinsufficiency versus a dominant negative effect (or
other unexpected effects). By grouping together the haploinsufficient DNMT3A patients and
comparing them to patients that have dominant negative alleles (e.g. R882), we will be able to
use existing data on gene expression and methylation phenotypes to see if there are common
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gene expression or methylation signatures that define DNMT3A haploinsufficiency in AML. By
comparing these signatures to corresponding data from our Dnmt3a+/- mice, we hope to be
able to arrive at an understanding of the role of DNMT3A in AML pathogenesis, which may have
important therapeutic implications for this disease.
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